immun
respons
elicit
anim
virus
histor
interest
well
current
practic
import
scienc
im
munolog
said
found
edward
jenner
well
known
enquiri
caus
effect
variola
vaccinia
publish
describ
inocul
variol
matter
arm
mari
barg
previous
cow
pox
note
remark
variol
matter
system
dispos
reject
excit
inflamm
speedili
produc
small
pox
first
descript
delay
hypersensit
reaction
vaccin
rash
produc
viru
infect
taken
exampl
allerg
reaction
von
pirquet
pioneer
studi
allergi
sinc
viru
infect
yet
treat
chemotherapi
immunoprophylaxi
isol
case
effec
tive
way
control
viru
diseas
import
epidemiolog
consequ
use
vaccin
smallpox
yellow
fever
polioviru
well
known
seem
like
vaccin
measl
rubella
viru
also
reduc
incid
diseas
veterinari
field
vaccin
canin
di
temper
canin
hepat
hog
cholera
newcastl
diseas
marek
diseas
chicken
highli
effect
thu
immunogen
anim
virus
consider
practic
import
enorm
amount
inform
accumul
antibodi
format
wide
rang
anim
form
inocul
virus
viru
vaccin
expect
small
virus
low
content
nucleic
acid
rel
simpl
structur
antigen
larg
virus
greater
content
nucleic
acid
complex
structur
herpesvirus
poxvirus
mani
antigen
small
virus
virus
intermedi
size
adenovirus
myxovirus
relationship
major
antigen
subunit
assembl
intact
virion
better
understood
chapter
repres
exampl
select
di
cussion
illustr
certain
gener
principl
concern
immunogen
anim
virus
way
resembl
differ
respons
antigen
brief
descript
structur
known
antigen
select
virus
follow
account
humor
secretori
respons
elicit
unexpect
result
obtain
cours
studi
im
mune
respons
influenza
virus
share
antigen
dif
fere
other
found
follow
exposur
one
viru
infect
second
viru
often
elicit
stronger
immun
respons
first
viru
second
phenomenon
origin
antigen
sin
one
first
exampl
immunologi
memori
studi
systemat
recent
un
derli
cellular
mechan
investig
problem
memori
format
b
lymphocyt
thymusdepend
thymusindepend
antigen
current
vigor
investiga
tion
observ
sequenti
respons
crossreact
viral
antigen
may
pertin
problem
thymu
depen
denc
viral
antigen
also
studi
result
pre
sent
commonli
studi
immun
respons
virus
neutral
antibodi
serum
high
sensit
precis
assay
base
neutral
plaqueform
virus
make
excel
model
system
much
inform
gener
interest
emerg
use
neutral
prove
complex
phenomenon
yet
fulli
understood
among
featur
studi
describ
sequenc
appear
neutral
capac
differ
class
immunoglobulin
avid
antibodi
addit
effect
complement
compon
exist
infecti
com
plex
virus
antibodi
macrophag
implic
mani
point
immun
respons
especi
antigen
process
present
possibl
b
lymphocyt
interact
interact
directli
virus
microorgan
mediat
cytotox
reaction
tumor
cell
cell
infect
virus
intracellular
parasit
capac
macrophag
support
viru
replic
thu
spread
infect
degrad
viru
aid
recoveri
infect
discuss
ontogeni
virucid
capac
review
emphasi
influenc
thymu
either
hormon
lymphocyt
prod
uct
interact
sensit
lymphocyt
infect
cell
requir
cell
surfac
chang
recogniz
lymphocyt
virusinduc
surfac
chang
describ
infect
virus
studi
repres
new
protein
glycoprotein
encod
viru
genom
other
result
rearrang
host
materi
derepress
host
gene
appear
n
e
w
host
antigen
receptor
includ
fc
ceptor
diminut
normal
present
antigen
includ
histocompat
antigen
report
antigen
modula
tion
cap
phenomena
previous
describ
nonvir
cell
surfac
antigen
also
found
viral
antigen
describ
delay
hypersensit
observ
mani
viru
infec
tion
recent
vitro
studi
confirm
exi
tenc
cellmedi
immun
respons
viral
antigen
regard
littl
curios
children
born
select
defici
cell
function
found
unduli
su
ceptibl
vaccinia
viru
herpesvirus
measl
viru
infec
tion
children
sever
hypogammaglobulinemia
gener
observ
experiment
anim
confirm
impor
tanc
cellmedi
immun
protect
certain
viru
infect
other
review
allison
burn
allison
thu
virus
elicit
power
cellmedi
respons
import
aspect
immunogen
sum
mari
present
evid
cellmedi
immun
respons
viral
antigen
particularli
observ
made
vitro
fact
infect
measl
varicella
mump
usual
occur
known
medic
practition
centuri
identifi
caus
virus
becam
clear
virus
abl
induc
longlast
immun
two
explan
put
forward
prolong
antibodi
product
absenc
reinfect
persist
viru
host
olitski
long
b
persist
clone
immunocompet
cell
burnet
explan
true
latter
phenomenon
well
known
evid
viru
persist
present
observ
traub
lymphocyt
choriomening
fection
mice
provid
evid
led
burnet
postul
exist
immunologi
toler
mice
congenit
infect
viru
antibodi
demonstr
serum
last
year
shown
com
plex
antibodi
virusspecif
antigen
accumul
kidney
give
rise
immunopatholog
glomerulonephr
similar
observ
made
murin
leukemogen
virus
thu
anim
complet
unrespons
viral
antigen
cooper
phenomena
perhap
haptencarri
na
ture
possibl
respons
autoimmun
phenomena
discuss
monograph
describ
reaction
vacci
nation
rash
produc
viru
infect
allerg
reaction
von
pirquet
drew
attent
depress
reaction
tuberculin
occur
measl
infect
first
report
suppress
immun
respons
viru
certain
viru
infec
tion
ldv
measl
viru
thymic
agent
dramati
calli
affect
immun
system
addit
import
clinic
consequ
infect
consid
interpret
laboratori
studi
immun
respons
intercurr
viru
infect
occur
anim
coloni
especi
sendai
viru
minut
viru
mice
mous
pneumon
viru
mous
hepa
titi
viru
behav
much
like
endogen
viru
undetect
anim
immunosuppress
frequent
found
nude
mice
passag
tumor
carri
ldv
virus
effect
viru
infect
immun
respons
discuss
virus
vari
consider
structur
antigen
com
plexiti
case
structur
known
antigen
well
character
relat
virion
structur
eg
adenoviru
influenza
viru
describ
small
virus
enterovirus
antigen
composit
rel
simpl
three
type
polioviru
instanc
two
tigen
distinguish
immunodiffus
complement
fixa
tion
cf
infecti
virion
contain
rna
dens
tigen
wherea
noninfecti
particl
c
coreless
antigen
hummel
et
al
antigen
convert
c
tigen
denatur
c
antigen
regard
pro
tein
attain
retain
configur
brought
complet
virion
associ
rnacontain
core
third
antigen
antigen
obtain
guanidin
degrad
viru
probabl
protein
precursor
viru
coat
scharffand
lewinton
human
infect
polioviru
develop
typespecif
antibodi
c
antigen
latter
neutral
viru
follow
section
structur
antigen
complic
virus
adenoviru
influenza
viru
paramyxovirus
togavirus
rhabdovirus
herpesvirus
describ
herpesvirus
form
famili
larg
envelop
virus
size
genom
doublestrand
dna
g
c
content
rang
differ
member
plummer
et
al
herpesvirus
natur
infect
man
tend
produc
latent
infect
focal
cytopatholog
divid
four
group
herp
simplex
hsv
cytomegalovirus
cmv
varicellazost
vz
epsteinbarr
eb
viru
virus
multipli
cell
nucleu
nake
icosohedr
nucleocapsid
seen
acquir
envelop
bud
inner
lamella
nuclear
membran
egress
membran
endoplasm
reticulum
shortli
infect
host
dna
protein
synthesi
ceas
viru
commenc
viral
mem
brane
protein
synthesi
begin
viral
dna
synthesi
glycosyl
viru
protein
occur
membran
ac
complish
host
enzym
hsv
virion
contain
least
virusspecif
protein
although
earlier
studi
show
hsv
could
agglutin
antisera
made
uninfect
host
cell
watson
wildi
recent
studi
reveal
essenti
host
protein
virion
see
review
roizman
hein
viral
structur
protein
includ
glycoprotein
made
first
two
hour
infect
viral
dna
replica
tion
begin
mani
structur
protein
hsv
eb
viru
perhap
herpesvirus
thu
repres
product
earli
func
tion
gene
situat
differ
usual
found
bacteriophag
papova
virus
structur
protein
code
late
gene
transcrib
viral
dna
repli
cation
protein
portion
membran
glycoprotein
viruscod
olshevski
becker
genet
variant
protein
determin
membran
phenomena
social
behavior
hsv
ie
whether
infect
cell
fuse
contigu
cell
clump
two
type
hsv
recogn
evid
present
typespecif
glycoprotein
present
infect
cell
virion
surfac
interact
antibodi
result
viru
neutral
cohen
et
al
powel
et
al
adenovirus
dna
virus
icosohedr
symmetri
least
human
type
blacklow
et
al
rosen
divid
subgroup
see
tabl
accord
hemagglutin
ha
characterist
rosen
norrbi
schlesing
review
structur
biolog
adenovirus
viru
protein
associ
dna
central
nucleoid
laver
et
al
surround
outer
protein
coat
capsid
capsid
contain
polygon
capsomer
hexon
form
triangular
facet
apic
made
penton
fig
penton
consist
vertex
hemagglutin
rat
partial
agglutin
enhanc
heterotyp
immun
sera
capsomer
penton
base
attach
knob
fiber
hexon
penton
isol
solubl
product
infect
cell
disrupt
virion
origin
three
antigen
describ
complementfix
hexon
group
antigen
antigen
common
adenovirus
except
avian
gal
viru
penton
group
antigen
b
antigen
toxic
cell
typespecif
fiber
antigen
c
antigen
awar
antigen
site
intact
virion
may
differ
determin
immun
sponta
neousli
occur
solubl
compon
subpop
ulat
hexon
particular
serotyp
detail
analys
adenoviru
antigen
structur
carri
use
purifi
capsid
subunit
specif
antisera
absorpt
ha
studi
subunit
vari
capac
ha
hexon
vertex
capsomer
show
capac
wherea
penton
fiber
subgroup
ii
iii
show
partial
ha
latter
due
unival
particl
sinc
dimer
penton
fiber
least
case
subgroup
iii
show
complet
ha
heterotyp
sera
react
group
subgroup
antigen
fiber
vertex
capsomer
enhanc
ha
aggreg
fiber
penton
polyval
complex
term
hemagglutin
enhanc
test
vertex
capsomer
identifi
abil
absorb
antibodi
thu
decreas
ha
normal
found
standard
prepar
penton
subsequ
ad
term
antibodi
consumpt
hec
test
hexon
appear
contain
sever
antigen
antigen
groupspecif
detect
c
f
test
hexon
antigen
ap
pear
locat
inner
aspect
capsid
sinc
antibodi
lack
hi
activ
seen
ultrastructur
examina
tion
moreov
process
disrupt
virion
result
increas
c
f
activ
presenc
typespecif
antigen
e
suggest
surpris
find
antihexon
sera
contain
neutral
antibodi
wilcox
ginsberg
kjellen
pereira
antibodi
antigen
ab
sorb
heterotyp
viru
hexon
leav
homotyp
anti
antibodi
activ
hemagglutin
inhibit
neutral
izat
assay
use
neg
stain
antibodi
shown
attach
outer
surfac
hexon
intact
virion
agglutin
virion
promin
might
account
hi
activ
antibodi
anoth
possibl
mechan
hi
activ
steric
hindranc
fiber
hemagglutinin
antibodi
attach
paravertex
hexon
latter
mechan
support
find
hi
activ
differ
antihexon
sera
inver
seli
relat
fiber
length
virus
test
serotyp
subgroup
iii
except
type
viru
differ
subgroup
ii
hexon
latter
consider
effici
induct
neutral
antibodi
antibodi
subgroup
iii
hexon
attach
hexon
shown
abil
sensit
viru
neutral
antiglobulin
antisera
absorpt
test
suggest
hexon
possess
minor
intrasubgroup
antigen
well
e
haas
pereira
recent
demonstr
neutral
capac
antibodi
direct
hexon
e
antigen
adenoviru
type
crystal
hexon
adenoviru
type
coupl
sepharos
immunoadsorb
column
prepar
antisera
purifi
hexon
adenoviru
type
pass
col
umn
adsorb
groupspecif
antibodi
unbound
mate
rial
possess
neutral
abil
type
viru
type
viru
subsequ
elut
antibodi
neutral
neither
viru
eleg
experi
demonstr
typespecif
e
tigen
crucial
hexon
antigen
involv
neutral
penton
separ
fiber
vertex
capsomer
guanidin
treatment
vertex
capsomer
groupspecif
b
antigen
toxin
activ
associ
capsomer
neutral
groupspecif
absorpt
experi
use
h
e
c
test
suggest
subgroup
intersubgroup
specif
recent
studi
use
antiglobulin
enhanc
neutral
virion
sensit
antisera
vertex
capsomer
confirm
indic
vertex
capsomer
intact
virion
subgroup
specif
found
monomer
solubl
subunit
fiber
contain
typespecif
c
antigen
ultrastruc
tural
examin
locat
distal
knob
end
particip
c
f
hi
reaction
antibodi
fiber
serotyp
abl
sensit
viru
neutraliza
tion
antiglobulin
perhap
neutral
directli
fiber
sub
group
ii
iii
also
contain
intrasubgroup
specif
antigen
locat
proxim
react
antibodi
vertex
capsomer
attach
antigen
activ
test
intersubgroup
specif
also
detect
wigand
fliedner
observ
adenoviru
strain
react
differ
hi
neutral
test
suggest
might
intermedi
strain
two
typespecif
antigen
e
differenti
hi
test
use
solubl
virionassoci
hemagglutinin
respect
analys
report
two
strain
hi
antigen
specif
relat
fiber
neutral
specif
hexon
norrbi
latter
relationship
complet
suggest
mutat
chang
hexon
previou
recombin
prototyp
practic
import
infect
mosaic
virus
might
result
hi
test
indic
one
prototyp
neutral
antibodi
protect
would
anoth
type
structur
influenza
viru
relat
fowl
plagu
viru
review
recent
laver
schulz
ortho
myxovirus
consist
helic
nucleocapsid
contain
nucleic
acid
rna
surround
pleiomorph
lipid
envelop
project
spike
glycoprotein
fig
nucleo
capsid
influenza
viru
uniqu
among
myxovirus
fragment
least
three
nucleoprotein
piec
contain
segment
viral
rna
viru
infect
nonglycosyl
viral
protein
term
membran
protein
protein
align
self
plasma
membran
viral
protein
accumul
cell
membran
exclus
host
protein
viral
protein
thu
form
discret
domain
cell
membran
bud
viru
occur
see
review
choppin
et
al
influenza
virion
diamet
cover
two
type
project
spike
arrang
hexagon
fashion
disrupt
viru
particl
lipid
solvent
spike
separ
subunit
hemagglutinin
neuraminidas
isol
hemagglutinin
spike
fig
rod
consist
trimer
glycoprotein
mw
dalton
molecul
reduc
condit
dissoci
yield
two
distinct
glycoprotein
hai
ha
molecular
weight
vari
viru
strain
hemagglutinin
appear
synthes
singl
protein
molecul
associ
endoplasm
reticulum
membran
rapidli
glycosyl
lazarowitz
et
al
stanley
haslam
compan
posttransl
cleavag
hemagglutinin
differ
variou
viru
strain
hostdepend
occur
plasma
membran
lazarowitz
et
al
lazarowitz
et
al
klenk
et
al
skehel
compan
cleavag
appear
affect
viru
infect
hemagglutinin
titer
stanley
et
al
neuraminidas
spike
shorter
distinct
hemagglutinin
spike
consist
tetram
subunit
glycoprotein
mw
dalton
wrigley
et
al
subunit
neur
aminidas
strain
may
consist
two
polypeptid
contrast
virion
protein
almost
code
viru
holland
kiehn
lipid
kate
et
al
carbohydr
howe
et
al
virion
host
specif
latter
alter
viru
antigen
specif
proteinbound
lipidbound
carbohydr
differ
treat
ment
viru
proteolyt
enzym
bromelin
remov
spike
leav
noninfecti
smoothsurfac
particl
contain
virion
lipid
fig
concanavalin
phytagglutinin
jack
bean
found
react
intact
virion
wherea
phytagglutinin
dolicho
bifloru
react
termin
sugar
blood
group
nacetylgalactosamin
react
spikeless
particl
glycolipid
moieti
expos
bromelin
treatment
klenk
et
al
likewis
antibodi
blood
group
could
absorb
spikeless
particl
intact
virion
earli
report
use
viral
prepar
probabl
contamin
host
cell
membran
fragment
indic
blood
group
antigen
b
forssman
antigen
could
detect
surfac
antigen
virion
grown
cell
possess
antigen
springer
schuster
howev
recent
studi
indic
progress
purif
viru
forssman
antigen
glyco
lipid
detect
virion
surfac
haheim
hauken
found
viral
lipid
access
tibodi
remov
virion
spike
bromelin
haheim
hauken
sulfat
glycopeptid
antigen
found
chick
allanto
caviti
hauken
et
al
howe
et
al
lee
et
al
found
liver
bile
adult
chicken
harbo
hauken
acquir
viru
grow
endoderm
cell
line
allanto
caviti
recent
studi
reveal
host
antigen
associ
spike
hemag
glutinin
neuraminidas
haheim
hauken
tibodi
host
antigen
react
carbohydr
moieti
rather
peptid
backbon
molecul
higginbotham
et
al
viru
genom
determin
four
major
antigen
hemagglutinin
neuraminidas
membran
protein
nucleoprotein
dif
ferenc
nucleoprotein
term
solubl
antigen
fig
influenza
wsn
virion
glycoprotein
remov
proteolyt
treatment
particl
neg
stain
uranyl
acet
glutaraldehyd
fixat
morpholog
suggest
doublelay
wall
ternal
strand
seen
particl
marker
schulz
divid
influenza
three
major
type
b
c
although
tibodi
intern
antigen
protein
fix
complement
neutral
hemagglutinatinginhibit
hi
activi
tie
probabl
unimport
immun
hemagglutinin
v
antigen
determin
strain
specif
react
neutral
ize
cf
hi
antibodi
great
genet
stabil
intern
antigen
v
antigen
expos
immunologi
selec
tion
undergo
frequent
minor
chang
result
influenza
epi
demic
major
antigen
shift
hemagglutinin
result
pan
demic
result
extens
chang
amino
acid
sequenc
ha
x
ha
reveal
tryptic
peptid
analys
may
volv
recombin
preexist
human
strain
anim
strain
laver
webster
neuraminidas
associ
glycoprotein
spike
differ
hemagglutinin
spike
undergo
antigen
chang
independ
v
antigen
paramyxoviru
genu
includ
number
common
virus
similar
orthomyxovirus
well
interest
differ
true
orthomyxovirus
host
factor
determin
composit
virion
lipid
coat
glycosyl
protrud
protein
spike
host
glycolipid
antigen
eg
blood
group
antigen
may
incorpor
virion
isacson
koch
howev
nucleocapsid
compos
singl
protein
speci
nonseg
rna
viral
nucleic
acid
repli
cation
occur
cytoplasm
rather
nucleu
within
genu
least
three
distinct
viru
group
parainfluenza
virus
includ
sendai
viru
simian
viru
mump
viru
newcastl
diseas
viru
ndv
consid
abl
antigen
crossreact
possess
hemagglutinin
neuraminidas
hemolyt
cellfus
activ
ha
neuraminidas
activ
ndv
sendai
viru
tozawa
et
al
scheid
choppin
resid
singl
glycoprotein
mw
hemolyt
cellfus
activ
sendai
viru
long
thought
associ
viru
protein
recent
studi
confirm
hosaka
shimiza
show
isol
viru
glycoprotein
viru
membran
lipid
inact
separa
teli
reconstitut
hemolyt
cellfus
activ
occur
recombin
scheid
choppin
recent
demonstr
sendai
viru
glycoprotein
mw
deriv
larger
precursor
natur
proteolyt
activ
vivo
trypsin
vitro
respons
hemolyt
cellfus
activ
virion
also
influenc
infect
tibodi
hemagglutininneuraminidas
glycoprotein
fusionhemolyt
glycoprotein
probabl
import
viru
neutral
antibodi
nucleocapsid
protein
intern
protein
measlesrinderpestcanin
distemp
group
paramyxo
virus
antigen
close
relat
one
anoth
lack
neuraminidas
recent
studi
indic
measl
virion
con
tain
six
polypeptid
two
glycoprotein
form
pro
ject
spike
martin
norrbi
cowork
correl
certain
test
structur
compon
measl
viru
norrbi
hammarskjold
antibodi
nucleocapsid
fix
complement
antibodi
inhibit
hemagglutin
hi
hemolysi
hli
must
react
surfac
compo
nent
find
hi
antibodi
block
hemolysi
hli
antibodi
slight
hi
activ
suggest
hemolysin
repres
separ
entiti
viru
envelop
follow
natur
measl
infect
nucleocapsid
c
f
antibodi
predomin
neutral
antibodi
correl
better
hli
hi
antibodi
norrbi
gollmar
subacut
scleros
panenceph
sspe
oligoclon
igg
antibodi
variou
viru
compon
found
especi
csf
vandvik
norrbi
one
case
popul
antibodi
hli
neutral
ize
hi
activ
identifi
patient
multipl
sclerosi
increas
amount
antibodi
measl
virion
compon
sera
csf
link
et
al
pathogenet
import
find
sspe
multipl
sclerosi
uncertain
respiratori
synciti
viru
class
temporarili
paramyxoviru
although
possess
envelop
spike
lack
hemagglutinin
neuraminidas
hemolyt
cellfus
activ
larg
famili
virus
includ
formerli
known
group
arbovirus
alphavirus
group
b
arbovirus
flavivirus
best
known
member
yellow
fever
viru
plu
small
number
unclassifi
structur
similar
virus
eg
rubella
viru
lactat
dehydrogenas
viru
alphavirus
flavivirus
group
basi
crossreact
hi
test
casal
complementfix
neutral
izat
crossprotect
test
specif
show
crossreact
within
group
ungroup
togavirus
serolog
relat
togavirus
consist
singlestrand
rna
enclos
coat
core
protein
rich
lysin
arginin
form
nucleocapsid
di
tinctiv
lipid
bilay
contain
carbohydr
appli
nucleocapsid
much
protein
influenza
virion
fig
peplom
compos
one
two
protein
speci
rich
hydrophob
amino
acid
facilit
attach
project
outward
lipid
coat
lipid
carbohydr
composit
virion
hostdetermin
pfefferkorn
hunter
strauss
et
al
renkonen
et
al
peplom
remov
proteas
leav
unchang
lipidco
nucleocapsid
compan
treatment
virion
deterg
yield
nu
cleocapsid
free
lipidglycoprotein
envelop
strauss
et
al
purifi
peplom
glycoprotein
capabl
elicit
neutral
ize
antibodi
block
neutral
activ
conval
cent
sera
isol
chikungunya
viru
igarashi
et
al
semliki
forest
viru
appleyard
et
al
ken
nedi
sindbi
viru
faulkner
dobo
bose
sagik
venezuelan
equin
enceph
viru
pedersen
et
al
two
distinct
envelop
glycoprotein
isol
sem
liki
forest
viru
possess
common
antigen
determin
kennedi
excis
carbohydr
moieti
variou
sugar
hydrolas
remov
antigen
must
therefor
part
polypeptid
rhabdovirus
vesicular
stomat
viru
vsv
rabi
viru
particularli
well
studi
bulletshap
envelop
rna
virus
long
diamet
fig
singlestrand
rna
mw
x
dalton
sociat
approxim
capsom
n
nucleo
capsid
protein
arrang
helix
turn
two
pro
tein
n
l
associ
nucleocapsid
influenza
viru
nonglycosyl
membran
protein
close
appli
nucleocapsid
protein
coat
turn
surround
hostderiv
lipid
coat
glycolipid
virion
hostdetermin
thu
may
possess
antigen
host
cell
antisera
uninfect
cell
react
highli
purifi
viru
grown
cell
one
studi
antigen
appear
host
hematosid
incorpor
glycolipid
portion
virion
cartwright
brown
glycoprotein
peplom
g
protein
mw
dalton
protrud
lipid
coat
remov
select
pro
teas
hemagglutinin
neutral
antigen
virion
cartwright
et
al
mcsharri
et
al
kelley
et
al
carbohydr
portion
glycoprotein
larg
hostspecifi
huang
strauss
grime
may
reflect
antigen
host
cell
membran
ansel
viru
glycoprotein
easili
purifi
thu
provid
tool
studi
alter
glycosyl
membran
protein
induc
cell
transform
moyer
summer
mix
infect
vsv
paramyxoviru
phenotyp
mix
occur
peplom
may
replac
vsv
vsv
virion
without
alter
overal
morpholog
mcsharri
et
al
virion
neutral
antibodi
known
host
glycoprotein
replac
viru
glycoprotein
peplom
nonion
deterg
use
sequenti
dissect
vsv
rabi
virion
infecti
ribonucleoprotein
remain
cartwright
et
al
variou
murin
leukemogen
virus
mulv
morpho
logic
indistinguish
one
anoth
diamet
consist
nucleoid
core
outer
shell
sur
round
membran
deriv
bud
possess
small
surfac
project
initi
rat
bear
mulvinduc
tumor
found
produc
c
f
precipit
antibodi
speci
groupspecif
gs
antigen
first
antigen
defin
name
anoth
shown
interspeci
tigen
name
antigen
well
typespecif
antigen
strain
mulv
speci
resid
protein
protein
mw
dalton
compris
total
virion
protein
intern
protein
sinc
neutra
lize
antibodi
react
antigen
wide
di
tribut
reticular
tissu
normal
mice
alway
cor
relat
presenc
infecti
mulv
viru
neutral
test
detect
viru
envelop
antigen
vea
two
close
relat
envelop
glycopeptid
molecu
lar
weight
dalton
contain
promin
groupspecif
common
mani
mulv
typespecif
limit
particular
viru
antigen
less
easili
detect
inter
speci
determin
neutral
studi
led
preliminarili
classif
laboratori
mulv
isol
categori
tabl
ii
high
incid
leukemia
mous
strain
akr
pro
duce
mulv
serolog
ident
gross
viru
gvea
hartley
et
al
cell
surfac
antigen
csa
mulvinfect
cell
first
defin
tumor
transplant
studi
anim
reject
tumor
graft
possess
specif
cytotox
antibodi
presenc
complement
lyse
tumor
induc
viru
antibodi
csa
neutral
antibodi
sinc
adsorpt
virusneutr
activ
purifi
viru
leav
cytotox
activ
serum
undiminish
pasternak
steev
also
immunoelectron
microscopi
studi
demon
strate
vea
csa
topograph
separ
region
cell
surfac
aokiei
al
crossreact
pattern
cytotox
antibodi
defin
two
major
subgroup
basi
csa
gross
friend
moloney
rauscher
fmr
typespecif
csa
deter
minant
analyz
gross
csa
found
mani
normal
preleukem
cell
highleukem
mous
strain
akr
contrast
fmr
determin
found
normal
cell
fmr
antigen
appear
intern
virion
protein
differ
friedman
et
al
although
princip
csa
mulvinfect
cell
found
surfac
infect
cell
ikeda
et
al
yoshiki
et
al
express
variou
gene
code
structur
protein
mulv
regul
mani
gene
lilli
pincu
row
multipl
copi
gene
code
viru
protein
may
present
cell
coordin
link
strand
et
al
revers
transcriptas
core
mulv
virion
carri
interspeci
speciesspecif
determin
park
et
al
interspeci
antigen
mulv
revers
transcriptas
crossreact
small
mammal
primat
chicken
sequenc
igm
igg
respons
viral
antigen
usual
like
observ
nonvir
antigen
complic
factor
humor
respons
virus
includ
persist
antigen
load
infect
continu
cell
tissu
destruct
viru
influenc
viru
immun
system
respons
rabbit
nonrepl
viral
antigen
studi
detail
poliomyel
type
pv
svehag
mandel
b
svehag
b
influenza
viru
webster
case
adequ
antigen
dose
short
induct
phase
hour
case
pv
igm
antibodi
ap
pear
follow
later
igg
antibodi
fig
small
dose
pv
produc
transient
igm
respons
day
declin
rate
consist
metabol
decay
rate
immunoglobulin
larger
dose
pv
elicit
igm
igg
tibodi
respons
igm
synthesi
continu
day
wherea
igg
first
detect
third
day
increas
third
week
thereaft
igg
level
remain
constant
week
persist
moder
titer
year
due
chronic
infect
sinc
polioviru
grow
rabbit
tissu
uvirradi
viru
gave
result
similar
find
tibodi
bacteriophag
guinea
pig
report
uhr
finkelstein
although
rate
fig
product
mercaptoethanolsensit
mercaptoethanolresist
antibodi
rabbit
immun
larg
dose
polioviru
svehag
mandel
tibodi
format
bacteriophag
less
antigendepen
dent
case
pv
interest
inform
immunologi
memori
come
experi
pv
low
dose
viru
elicit
igm
respons
detect
memori
repeat
small
dose
pv
monthli
interv
elicit
transient
ident
igm
respons
fig
howev
second
small
dose
pv
ad
minist
day
first
day
antibodi
begun
declin
larg
secondari
respons
consist
exclus
antibodi
occur
titer
rose
sec
ondari
respons
began
day
inocul
pv
persist
day
result
suggest
immunologi
memori
igm
antibodi
product
exist
shortliv
earli
larg
secondari
respons
show
immunocompet
cell
primari
respons
die
day
antibodi
releas
requir
antigen
stimul
continu
antibodi
produc
tion
similar
result
obtain
pig
system
studi
natur
experiment
polioviru
infect
human
use
attenu
viru
larg
confirm
find
product
antibodi
rabbit
repeat
immun
small
dose
polioviru
antibodi
produc
respons
tran
sient
almost
ident
svehag
mandel
rabbit
previous
discuss
level
neutral
igm
tibodi
rise
rapidli
natur
infect
reach
maximum
titer
week
declin
undetect
level
month
svehag
mandel
ogra
et
al
igg
titer
rise
pro
long
period
may
attain
peak
level
month
iga
antibodi
detect
week
infect
rise
least
ensu
week
earli
neutral
tibodi
low
avid
sabin
although
cf
antibodi
c
antigen
attain
maximum
level
month
persist
year
neutral
antibodi
decreas
onefourth
peak
titer
year
persist
near
level
decad
ogra
et
al
compar
humor
respons
live
inactiv
vaccin
infant
see
fig
begin
month
age
monthli
dose
trival
inactiv
viru
subcutan
live
viru
type
type
success
month
oral
administ
booster
given
month
age
poliovirusbind
antibodi
titer
determin
radioimmunodiffus
neutral
antibodi
assay
type
viru
perform
sera
secret
matern
deriv
igg
inactiv
vaccin
day
fig
product
igm
igg
iga
antibodi
polioviru
type
serum
secret
immun
three
dose
trival
inactiv
viru
monthli
interv
begin
month
age
ogra
et
al
live
vaccin
day
fig
product
igm
igg
iga
antibodi
polioviru
type
serum
secret
immun
live
attenu
polioviru
type
given
sequenti
monthli
interv
begin
month
age
ogra
et
al
tibodi
detect
low
titer
onefourth
infant
age
month
sera
contain
igm
igm
igg
detect
day
first
vaccin
dose
igm
titer
rose
rapidli
igg
becam
maxim
second
week
declin
undetect
level
week
igm
declin
slowli
recipi
inactiv
viru
repeat
antigen
stimul
dose
igg
titer
group
continu
rise
week
level
serum
iga
titer
detect
week
initi
immun
rose
slowli
period
booster
month
igm
titer
show
transient
rise
previou
level
thu
duplic
find
ing
rabbit
fig
recipi
live
viru
neutral
iga
nasal
duoden
secret
day
per
sist
least
day
duoden
day
nasal
recipi
inactiv
viru
secret
iga
antibodi
polioviru
studi
guinea
pig
infect
arbovirus
bellanti
et
al
human
infect
mump
viru
daugharti
et
al
coxsacki
viru
schmidt
et
al
influ
lehrich
et
al
demonstr
igm
igg
pattern
similar
follow
polioviru
infect
suggest
pattern
antibodi
respons
gener
phenom
non
igm
respons
follow
natur
influenza
infect
im
muniz
appear
uniqu
one
studi
igm
exclus
form
brown
oleari
particular
antigen
viru
appear
capabl
elicit
respons
specif
class
immunoglobulin
nonvir
tigen
schirrmach
rajewski
cowan
brown
smale
shown
igm
igg
produc
guinea
pig
infect
footandmouth
diseas
viru
specif
di
tinctiv
antigen
determin
viru
particl
describ
differenti
reaction
antibodi
hsv
antigen
infect
cell
patient
wart
produc
igm
antibodi
human
wart
viru
goff
et
al
pyrhonen
penttinen
recent
lee
et
al
report
normal
mous
sera
contain
tibodi
react
antigen
determin
structur
pro
tein
mulv
antibodi
fraction
react
one
protein
p
l
sever
explan
offer
preferenti
elicit
particular
immunoglobulin
class
viral
antigen
triv
ial
explan
find
igm
particular
antigen
igm
respons
transient
unless
continu
antigen
stimul
exclus
igm
respons
may
occur
small
immunogen
stimuli
discuss
thu
wart
viru
grow
epidermi
readi
access
bloodstream
lymphat
immun
host
led
suggest
suscept
recurr
attack
wart
may
relat
fail
ure
small
dose
antigen
promot
igg
respons
presenc
latter
good
indic
heal
pyrhonen
penttinen
genet
control
immun
respons
certain
antigen
demonstr
guinea
pig
mice
appear
control
ir
gene
complex
see
benacerraf
mcdevitt
mcdevitt
landi
nonrespond
pro
duce
igm
antibodi
specif
antigen
grumet
unless
certain
condit
allogen
stimulu
impos
ordal
grumet
similar
situat
viral
antigen
may
also
occur
yet
describ
howev
increas
humor
respons
measl
viru
associ
man
arnason
et
al
increas
incid
multipl
sclerosi
associ
associ
optic
neuriti
often
evolv
clinic
multipl
scle
rosi
also
patient
optic
neuriti
normal
level
tibodi
measl
viru
associ
high
titer
antibodi
measl
viru
multipl
sclerosi
may
thu
reflect
preval
high
titer
viru
peopl
genotyp
mani
exampl
genet
control
resist
infect
within
speci
known
thu
sever
major
gene
confer
resist
chicken
chick
cell
infect
particular
strain
avian
leukemogen
virus
rou
virus
coat
control
murin
leukemogenesi
multigen
differ
gene
control
viral
express
gene
viral
replic
gene
resist
gross
viru
virustransform
cell
gene
lilli
pincu
row
gene
link
influenc
late
diseas
pattern
infer
howev
mecha
nism
thought
involv
immun
respons
immunopatholog
diseas
caus
lcm
viru
infect
adult
mice
report
associ
oldston
et
al
find
ing
univers
found
laboratori
possibl
viru
strain
differ
await
detail
immunologi
analysi
virus
infect
seromuc
surfac
respiratori
alimentari
tract
must
pass
first
line
defens
consist
secr
tori
antibodi
inhibitori
mucoprotein
secret
franci
first
note
presenc
antiinfluenz
antibodi
human
nasal
secret
year
thought
viru
infect
mucou
membran
could
confer
specif
local
immun
clear
main
antibodi
seromuc
secret
iga
although
compensatori
increas
level
immunoglobulin
especi
igm
occur
secret
peopl
iga
defici
see
tomasi
bienenstock
thu
tibodi
nasal
secret
rhinovirus
parainfluenza
viru
smith
et
al
influenza
viru
alford
et
al
predominantli
iga
howev
role
iga
antibodi
recoveri
viru
infect
preven
tion
reinfect
less
clear
fazeka
de
st
groth
graham
report
immu
niti
mice
reinfect
influenza
viru
close
corr
late
presenc
antibodi
nasal
secret
tibodi
serum
sever
group
investig
report
parenter
administr
inactiv
virus
increas
level
serum
igg
igm
antibodi
level
iga
antibodi
nasal
secret
wherea
natur
infect
result
format
iga
secretori
antibodi
better
resist
reinfect
smith
et
al
alford
et
al
nec
essarili
impli
iga
respons
resist
reinfect
natur
infect
could
effect
clude
local
stimul
lymphocyt
claim
local
iga
product
protect
follow
aerosol
administr
inac
tivat
influenza
viru
waldman
et
al
con
firm
laboratori
shore
et
al
work
subject
requir
one
argument
sabin
support
live
polioviru
immun
would
stimul
local
secretori
antibodi
product
therebi
limit
excret
viru
transmiss
popul
ogra
present
evid
produc
tion
iga
antibodi
local
reaction
immun
select
segment
larg
intestin
subject
doublebarrel
colostomi
induc
iga
antibodi
respons
polioviru
immun
segment
littl
respons
elsewher
ever
subcutan
immun
kill
polioviru
elimin
paralyt
diseas
also
transmiss
viru
swedish
popul
shown
larg
scale
examin
fece
person
admit
hospit
reason
perkin
defici
secretori
iga
rare
occur
person
western
europ
north
america
individu
al
remain
healthi
although
recurr
sinopulmonari
gastrointestin
infect
schwartz
buckley
thu
individu
igg
igm
antibodi
appear
abl
substitut
iga
antibodi
secret
exposur
anim
antigen
format
tibodi
cell
b
lymphocyt
lineag
requir
helper
effect
lymphocyt
miller
et
al
given
rise
con
cept
thymu
depend
antigen
antigen
depend
other
lymphocyt
normal
humor
respons
origin
thymu
depend
defin
term
amount
serum
antibodi
form
antigen
lym
phocytedepriv
anim
later
found
igm
respons
less
depend
lymphocyt
immunoglobulin
class
humor
respons
certain
thymu
independ
antigen
pneumococc
polysaccharid
type
iii
regul
lymphocyt
thymu
depend
thu
rela
tive
term
depend
anim
speci
strain
well
mode
antigen
present
gener
thymusindepend
antigen
larg
slowli
metabol
molecul
repeat
antigen
de
termin
epitop
might
expect
virus
mani
possess
antigen
polyval
inher
structur
could
epitop
proper
repeat
spatial
rela
tionship
immunogen
thymusindepend
recent
avail
athym
nude
mous
neonat
thymectomi
treatment
al
use
deplet
anim
lymphocyt
ascertain
thymu
depend
viru
antigen
although
method
lymphocyt
deplet
effect
present
standard
result
obtain
review
thu
neonat
thymectomi
abolish
product
hi
tibodi
polyoma
viru
mice
mori
et
al
rat
allison
taylor
influenza
viru
svetmoldavski
et
al
coxsacki
viru
cite
mori
et
al
mice
titer
complementdepend
neutral
tibodi
probabl
igm
hsv
mice
neonat
thymectom
similar
control
mice
mori
et
al
method
lymphocyt
deplet
pretreat
mice
al
diminish
product
hi
antibodi
vaccinia
viru
hirsch
et
al
c
f
antibodi
lcm
viru
hirsch
et
al
hi
antibodi
influenza
viru
hirsch
mur
phi
addit
ineffect
method
lymphocyt
depriv
studi
continu
antigen
present
occur
viru
infect
must
consid
svetmoldavski
et
al
demonstr
abrog
antibodi
respons
sheep
erythrocyt
observ
neonat
thymectom
mice
overcom
repeat
immun
mori
et
al
report
neonat
thymectom
mice
inocul
japanes
en
cephal
viru
diminish
hi
titer
howev
rose
normal
level
repeat
inocul
studi
suggest
thymu
depend
viru
antigen
thind
price
report
markedli
depress
level
neutral
antibodi
langat
viru
togaviru
mice
neo
natal
thymectom
infect
week
later
virelizi
et
al
recent
analyz
role
cell
helper
effect
format
antibodi
influenza
viru
hemagglutinin
two
hemagglutinin
contain
crossreact
determin
strainspecif
determin
use
antibodi
format
could
quantit
independ
immunodiffus
immun
thymectom
irradi
bonemarrow
reconstitut
txbm
mice
show
strong
thymu
allison
unpublish
observ
observ
neonat
thymectom
mice
infect
adult
hsv
level
serum
neutral
antibodi
much
lower
intact
anim
c
allison
w
h
burn
confirm
find
txbm
mice
nude
mice
unpublish
observ
discrep
anci
find
previou
report
concern
hsv
influenza
viru
probabl
stem
use
mice
inadequ
deplet
lymphocyt
earlier
report
sinc
mice
sham
thymectom
irradi
bonemarrow
reconstitut
make
poor
respons
antigen
month
reconstitut
howard
et
al
mitchel
humphrey
lesion
addit
lymphocyt
deplet
must
present
txbm
mice
although
nude
mice
may
possess
abnorm
addi
tion
present
recogn
probabl
best
imal
studi
thymu
depend
w
h
burn
unpublish
observ
compar
humor
respons
nude
mice
normal
nu
litterm
infect
number
virus
insignific
low
probabl
igm
level
neutral
ize
antibodi
found
nude
mice
infect
coxsacki
bl
viru
encephalomyocard
viru
west
nile
viru
vsv
hsv
hi
antibodi
detect
infect
influenza
sendai
virus
c
f
antibodi
detect
infect
mous
adenoviru
howev
infect
sindbi
viru
sult
high
titer
neutral
antibodi
sole
igm
class
titer
compar
control
litterm
sustain
week
antigen
sindbi
viru
react
neutral
antibodi
two
membran
glycoprotein
use
rabbit
antisera
kennedi
demonstr
antigen
determin
semliki
forest
viru
alphaviru
similar
sindbi
viru
polypeptid
portion
rather
carbo
hydrat
moieti
envelop
glycoprotein
interest
determin
thymusindepend
antigen
determin
sindbi
viru
similarli
resid
protein
part
molecul
recent
natur
antibodi
sera
nude
mice
detect
neutral
xenotrop
viru
isol
mice
cross
h
mors
j
hartley
person
commun
pre
sumabl
antibodi
predominantli
igm
direct
viral
envelop
protein
andor
glycoprotein
theoret
ground
might
suppos
vaccin
seri
antigen
relat
viral
vaccin
would
produc
broad
immun
virus
group
eg
type
influenza
virus
flavivirus
howev
aim
difficult
achiev
caus
properti
immunologi
memori
franci
call
origin
antigen
sin
respons
variou
age
group
human
popul
vaccin
differ
strain
influ
enza
viru
show
respons
individu
domin
throughout
life
type
jf
antibodi
produc
result
first
exposur
influenza
viru
franci
franci
davenport
hennessi
type
respons
char
acterist
infect
longliv
anim
viru
sever
crossreact
antigen
type
eg
flavi
virusesgroup
b
arthropodbon
virus
hearn
rainey
paramyxovirus
van
der
veen
sonderkamp
enterovirus
mieten
et
al
reproduc
laboratori
anim
either
success
infect
crossreact
virus
success
vaccin
inact
vaccin
made
crossreact
virus
phenomenon
also
observ
mice
immun
purifi
crossreact
influenza
viru
hemagglutinin
virel
et
al
analog
respons
port
anim
immun
crossreact
serum
albumin
hla
antigen
hapten
westaway
et
al
recent
port
sequenti
infect
rabbit
relat
togavirus
crossreact
antibodi
produc
rechalleng
igg
class
igm
antibodi
specif
recent
immun
viru
geograph
area
flaviviru
infect
common
diagnosi
difficult
crossreact
antibodi
recal
phenomenon
determin
igm
specif
permit
diagnosi
edelman
pariyanonda
thu
origin
antigen
sin
phenomenon
gener
interest
theoret
point
view
practic
import
immun
program
epidemiolog
para
doxic
sinc
impli
qualit
failur
specif
im
munologi
memori
cellular
basi
phenomenon
un
known
investig
detail
begun
use
two
purifi
influenza
hemagglutinin
h
possess
specif
well
crossreact
determin
virelizi
et
al
b
mention
format
antibodi
determin
thymusdepend
howev
thymu
depend
antibodi
format
crossreact
determin
could
overcom
repeat
inocul
hemagglutinin
txbm
mice
indic
presenc
memori
anim
strong
secondari
type
respons
observ
prime
thymusdepriv
mice
reconstitut
syngen
virgin
thymu
cell
show
spe
cific
immunologi
memori
elicit
determin
despit
absenc
detect
antibodi
secret
observ
interpret
exampl
immunologi
recognit
memori
mediat
b
lymphocyt
suggest
helper
effect
lymphocyt
exert
late
stage
differenti
specif
popul
b
cell
antibodysecret
cell
find
similar
roelant
askona
zitron
person
commun
nonvir
antigen
similar
interpret
might
explain
result
yamanouchi
et
al
report
acut
infect
rinderpest
viru
de
press
primari
respons
rabbit
sheep
erythrocyt
left
intact
secondari
respons
reimmun
week
later
rinderpest
viru
like
measl
viru
close
resembl
may
transient
impair
cell
helper
effect
yet
allow
b
lymphocyt
prolifer
sever
experi
shown
b
lymphocyt
memori
respons
origin
antigen
sin
thu
spleen
cell
mice
prime
h
transfer
normal
irradi
recipi
ent
latter
challeng
h
secondari
respons
specif
h
determin
well
crossreact
determin
obtain
treatment
spleen
cell
sera
compl
ment
affect
type
recal
howev
similar
experi
ment
use
irradi
recipi
show
addit
mem
ori
respons
special
type
recal
lymphocyt
memori
increas
specif
respons
determin
first
hemagglutinin
h
crossreac
tive
decreas
infecti
titer
mix
antibodi
viru
term
neutral
review
svehag
studi
carri
fluid
phase
vitro
system
viruscellantibodycompl
compon
present
uniqu
featur
influenc
host
cell
shown
kjellen
schlesing
found
differ
level
residu
infect
vsv
virusantibodi
complex
assay
chick
human
cell
complex
viru
mammalian
tibodi
effici
neutral
propag
mam
malian
cell
chicken
cell
wherea
chicken
antibodi
effect
chicken
cell
philipson
report
analog
find
polioviru
assay
monkey
human
cell
other
made
similar
observ
variou
virushost
cell
system
lafferti
hawk
thu
neutral
complex
process
involv
three
compon
viru
antibodi
host
cell
neutral
vivo
leukocyt
accessori
factor
present
may
differ
import
respect
ob
serv
cell
cultur
initi
interact
viru
antibodi
exten
sive
studi
worker
found
interact
revers
eg
influenza
viru
burnet
et
al
fazeka
de
st
groth
lafferti
other
felt
essenti
irrev
sibl
eg
polioviru
dulbecco
et
al
mandel
philipson
adenoviru
kjellen
ndv
granoff
hsv
yoshino
taniguchi
philipson
use
twophas
aqueou
polym
system
distribut
free
tibodybound
viru
differ
phase
examin
interact
polioviru
variou
immunoglobulin
short
lag
igm
tibodi
bound
viru
irrevers
igg
antibodi
follow
firstord
kinet
bound
viru
rapidli
irrevers
use
countercurr
distribut
procedur
total
dilut
factor
small
fraction
poliovirusantibodi
complex
could
di
sociat
mandel
show
complex
stabl
day
resuspend
media
without
antibodi
howev
dissoci
occur
infecti
polioviru
recov
ex
posur
complex
acid
alkali
mandel
treatment
fluorocarbon
ketler
et
al
sonic
keller
exposur
proteolyt
enzym
keller
fc
part
immunoglobulin
molecul
determin
mani
biolog
properti
complement
fixat
placent
transfer
bind
certain
cell
influenc
viru
neutral
examin
indirectli
observ
neutral
fab
frag
ment
puriti
fab
fragment
vari
differ
experi
gener
fab
found
neutral
influenza
viru
lafferti
polioviru
vogt
et
al
hsv
ldv
notkin
et
al
adenoviru
type
kjellen
kjellen
antibodi
proper
amount
agglutin
coat
virion
prevent
adsorpt
shown
ndv
rubin
franklin
polioviru
mandel
keller
ever
virusantibodi
complex
sometim
adsorb
host
cell
although
complex
contain
larger
igm
slowli
contain
igg
perhap
greater
steric
hin
dranc
mandel
adsorb
complex
may
penetr
slowli
suscept
neutral
ad
antisera
nonadsorb
free
viru
rubin
franklin
rubin
mandel
correl
antigen
structur
neutral
made
sever
virus
exampl
con
sider
neutral
adenoviru
take
place
two
step
firm
initi
antibodyviru
bind
follow
increas
inactiv
kjellen
although
either
unival
bival
fab
fragment
bind
adenoviru
block
whole
antibodi
hi
activ
neither
fragment
block
neutral
activ
whole
antibodi
sinc
ha
mediat
fiber
antigen
neutral
requir
interact
hexon
e
antigen
could
explain
fab
fragment
bind
e
bind
fab
frag
ment
antisera
prepar
capsid
subunit
would
clarifi
sinc
antisera
hexon
e
antigen
neutral
wilcox
ginsberg
kjellen
pereira
philipson
fiber
usual
kjellen
pereira
pettersson
et
al
neutral
antibodi
may
prevent
adsorp
tion
host
cell
may
alter
later
step
uncoat
intrasubgroup
heterotyp
antisera
neutral
adenoviru
type
low
ph
addit
heterotyp
sera
homotyp
sera
normal
ph
enhanc
neutral
kjellen
pereira
suggest
low
ph
interact
homotyp
antibodi
outer
aspect
hexon
might
expos
inner
site
sub
group
specif
could
react
heterotyp
antibodi
enhanc
neutral
accord
view
conform
chang
hexon
import
adenoviru
neutral
possibl
lead
faulti
uncoat
degrad
heterophag
vacuol
describ
antibodycomplex
ndv
vaccinia
dale
kajioka
silverstein
marcu
dale
footandmouth
diseas
viru
fmdv
icosohedr
particl
shown
three
class
antibodybind
site
brown
smale
one
protein
subunit
face
particl
separ
viru
heat
acid
treatment
react
igg
site
vertic
bind
igg
one
trypsin
sensit
site
tachment
igm
antibodi
neutral
studi
antisera
whole
viru
adsorb
trypsintr
viru
subunit
indic
vertex
site
involv
neutral
face
site
rowland
et
al
virion
glycoprotein
appear
import
antigen
involv
neutral
mani
virus
g
protein
vsv
glycoprotein
form
spike
protrud
viru
coat
solubil
deterg
purifi
antisera
produc
protein
good
neutral
activ
kelley
et
al
envelop
glycoprotein
anoth
rhabdoviru
rabi
also
ex
tract
purifi
induc
neutral
antibodi
protect
anim
later
challeng
rabi
viru
offer
new
form
vaccin
cohen
et
al
report
purif
hsvinfect
cell
virion
glycoprotein
capabl
stimul
rabbit
monoprecipitin
antisera
neu
traliz
hsv
worker
isol
envelop
glycoprotein
hsv
type
react
typespecif
neutral
antibodi
powel
et
al
neutral
influenza
viru
result
primariili
interac
tion
antibodi
hemagglutinin
although
high
concentr
antibodi
neuraminidas
neutral
viru
strain
kilbourn
et
al
antibodi
hemagglutinin
prevent
virion
attach
cell
antibodi
neuraminidas
antibodi
prevent
viropexi
presenc
virion
remain
cell
surfac
dourmashkin
tyrrel
antineuraminidas
may
also
interfer
egress
viru
infect
cell
capac
natur
antibodi
thought
igm
earli
immun
igm
antibodi
neutral
virus
increas
reaction
complement
system
normal
human
sera
rabbit
earli
immun
sera
requir
complement
neutral
coliphag
wherea
late
immun
sera
human
rabbit
muschel
toussaint
inocul
rabbit
hsv
earli
sera
contain
igm
igg
antibodi
requir
complement
neutral
taniguchi
late
sera
contain
igm
igg
could
neutral
hsv
without
complement
complement
increas
igm
neutral
ize
capac
rais
neutral
rate
constant
titer
late
igg
hampar
et
al
neutral
antibodi
rubella
viru
especi
igm
earli
igg
also
requir
compl
ment
rawl
et
al
leerhoy
ineffici
earli
late
igm
earli
igg
antibodi
equin
arter
viru
neutral
affect
complement
except
find
observ
late
igg
antibodi
viru
strongli
depend
complement
neutral
hyllseth
pettersson
radwan
burger
find
note
sera
five
speci
therefor
probabl
charac
terist
viru
rather
sourc
antibodi
clear
complement
increas
neutral
sinc
antibodi
earli
immun
sera
often
low
avid
viru
possibl
reaction
complement
stabil
virusan
tibodi
complex
hsv
system
howev
complex
viru
earli
sera
stabl
mechan
must
oper
yoshino
taniguchi
complex
neutral
ize
late
sera
bind
earli
serum
antibodi
must
leav
crucial
site
infect
expos
accumul
com
plement
protein
virion
surfac
may
cover
import
site
interfer
adsorpt
penetr
uncoat
aggreg
viru
particl
also
occur
virusantibodi
complex
hsv
equin
arter
viru
ad
sorb
cell
surfac
found
suscept
complement
earli
period
cellcomplex
interact
suggest
complement
influenc
step
later
adsorpt
yoshino
taniguchi
radwan
burger
sinc
penetr
virusantibodi
complex
cell
known
prolong
com
pare
viru
alon
reaction
complement
stage
may
import
sequenc
complement
compon
reaction
virusantibodi
complex
antigenantibodi
system
studi
use
purifi
compon
complement
hsv
ndv
complex
earli
igm
shown
c
l
requir
neutral
effect
suboptim
amount
supplement
addit
daniel
et
al
linscott
levinson
similar
find
com
plement
enhanc
hi
activ
earli
igm
antibodi
bound
influenza
viru
report
reno
hoffman
oldston
et
al
found
complementenhanc
neutral
polyoma
viru
requir
well
c
l
enhanc
neu
traliz
occur
primarili
agglutin
virusantibodi
complex
electron
microscop
studi
demonstr
avian
infec
tiou
bronchiti
viru
coronaviru
hostderiv
lipid
coat
contain
project
undergo
complementdepend
virolysi
similar
complementdepend
erythrocyt
lysi
berri
almeida
almeida
waterson
antibodi
fect
chicken
react
virusspecifi
project
recogn
virion
membran
self
hostderiv
howev
antibodi
rabbit
immun
viru
grown
chicken
react
virion
membran
project
wherea
rabbit
antibodi
uninfect
chicken
cell
react
mem
brane
neutral
capac
three
antisera
enhanc
complement
electron
microscopi
show
complement
tach
project
antibodi
bound
hole
membran
complement
react
antibodi
site
complementmedi
virolysi
also
describ
rubella
viru
almeida
laurenc
influenza
viru
almeida
waterson
gross
leukemogen
akr
viru
oroszlan
gilden
equin
arter
viru
radwan
et
al
preced
discuss
consid
classic
com
plement
activ
pathway
initi
requir
convers
c
l
c
l
subsequ
interact
c
l
activ
remain
compon
interest
recent
turn
toward
altern
pathway
activ
without
interact
preced
three
compon
osier
sandberg
certain
immunoglobulin
immunoglobulin
fragment
bind
antigen
activ
complement
altern
pathway
guinea
pig
antibodi
effici
activ
complement
classic
pathway
interact
fc
portion
tibodi
molecul
c
l
essenti
howev
f
ab
fragment
immunoglobulin
activ
complement
via
altern
path
way
l
sandberg
person
commun
use
f
ab
frag
ment
antihsv
determin
whether
complementdepend
enhanc
hsv
neutral
occur
altern
path
way
found
f
ab
fragment
bound
viru
effici
enhanc
neutral
parent
undigest
antibodi
furthermor
minim
lysi
hsvinfect
rabbit
kidney
cell
altern
pathway
bind
ing
f
ab
fragment
cell
membran
virus
must
examin
conclus
drawn
concern
impor
tanc
altern
pathway
viru
neutral
may
specif
requir
first
complement
compon
enhanc
neutral
virus
vivo
consequ
complement
reaction
virusan
tibodi
complex
often
detriment
host
produc
arter
glomerulonephr
choroid
oldston
dixon
addit
bound
complex
may
facil
itat
attach
macrophag
neutrophil
b
lympho
cyte
receptor
could
enhanc
clearanc
cell
viral
growth
restrict
convers
facil
itat
viru
growth
spread
cell
suscept
residu
infect
viru
exposur
excess
antibodi
call
persist
fraction
presenc
natur
review
majer
burnet
et
al
first
note
exist
nonneutraliz
fraction
anim
viru
studi
mani
virus
vitro
picornavirus
togavirus
myxovirus
herpesvirus
poxvirus
reovirus
vivo
lactat
dehydrogenas
viru
hl
viru
visna
viru
aleutian
mink
diseas
viru
demonstr
gener
phe
nomenon
viru
persist
fraction
genet
variant
shown
studi
demonstr
similar
behavior
nonneutr
viru
progeni
parent
popul
neutral
izat
test
dulbecco
et
al
notkin
et
al
hahon
majer
link
persist
fraction
shown
consist
virusan
tibodi
complex
physiochem
method
densitygradi
centrifug
kjellen
countercurr
distribut
philipson
ratezon
centrifug
howev
studi
base
use
antiglobulin
ash
notkin
antibodi
direct
antivir
immunoglobulin
react
virusantibodi
complex
increas
neutral
note
notkin
et
al
found
per
sist
infecti
viru
plasma
mice
infect
ldv
virusantibodi
complex
could
neutral
treat
ment
antisera
mous
immunoglobulin
rabbit
tibodi
hsv
ash
notkin
found
persi
tent
fraction
could
markedli
reduc
antisera
rabbit
immunoglobulin
although
antisera
effect
viru
sensit
use
antiglobulin
variou
immunoglobulin
class
shown
igm
igg
iga
sensit
viru
studi
unfraction
antisera
demonstr
sensit
antibodi
mice
infect
ldv
igg
iga
antimous
igm
neutral
persist
fraction
human
tisera
venezuelan
equin
enceph
vee
viru
likewis
sensit
igg
iga
igm
antibodi
hahon
h
p
r
e
al
could
sensit
hsv
igm
antibodi
rabbit
late
immun
sera
earli
sera
site
antiglobulin
interact
examin
univa
lent
antivir
fab
fragment
found
sensit
hsv
ash
et
al
polioviru
keller
antifab
could
neu
traliz
sensit
vee
viru
hahon
indic
fab
portion
sensit
antibodi
bind
antiglobulin
result
neutral
persist
fraction
vee
viru
could
also
neutral
antiallotyp
antiglobulin
fc
allotyp
antifc
antiglobulin
demonstr
fc
portion
also
bind
antiglobulin
viru
sensit
gener
thought
occur
antibodi
attach
noncrit
site
virion
exposur
requir
initi
infect
may
hinder
attach
antibodi
critic
site
suboptim
amount
antisera
react
viru
found
subsequ
addit
tiglobulin
larg
fraction
viru
sensit
neutral
antivir
antibodi
ash
notkin
notkin
et
al
thu
found
ldv
sensit
occur
sooner
neutral
ldv
hsv
sensit
increas
neutral
constant
diminish
presum
antiglobulin
bind
antivir
antibodi
noncrit
site
steric
hinder
interact
viru
cell
accordingli
unival
antiglobulin
fab
fragment
neutral
sensit
viru
less
well
larger
whole
antiglobulin
notkin
et
al
rheumatoid
factor
rf
human
igm
specif
fc
portion
aggreg
complex
igg
antibodi
also
found
react
virusigg
antibodi
complex
ash
et
al
rabbit
human
antihsv
igg
antibodi
react
hsv
human
rf
reduct
persist
fraction
hsviggrf
complex
occur
unless
prepar
al
low
react
complement
antihuman
igm
tiglobulin
appar
attach
rf
provid
new
site
complement
reaction
attach
complex
fab
frag
ment
antihsv
use
sensit
viru
enhanc
neutral
observ
reaction
complement
antiigm
presum
inabl
rf
attach
fab
fragment
hayashi
et
al
shown
rf
bind
infect
cell
expos
antivir
antibodi
whether
rf
play
protect
role
vivo
enhanc
neutral
izat
infecti
virusantibodi
complex
unknown
alterna
tive
enhanc
complementfix
capac
complex
may
lead
increas
patholog
immun
complex
diseas
mim
summar
evid
virus
introduc
lung
site
taken
macrophag
local
tissu
lymph
node
demonstr
immunofluoresc
likewis
virus
enter
blood
primari
site
multipl
introduc
bloodstream
eg
arthropod
vector
remov
kupffer
cell
macrophag
line
blood
sinus
usual
virus
multi
pli
suffici
well
macrophag
adult
host
spread
cell
highli
suscept
hepat
paren
chymal
cell
howev
macrophag
barrier
bypass
ex
pose
liver
parenchym
cell
directli
infect
eg
inject
viru
bile
duct
lethal
infect
widespread
mul
tiplic
viru
parenchym
cell
result
similarli
brain
highli
suscept
organ
intracerebr
inject
mani
virus
adult
anim
result
lethal
infect
macrophag
repres
import
barrier
spread
fection
relationship
capac
viru
multipli
macrophag
virul
adult
anim
relationship
exist
strikingli
demonstr
major
genet
factor
determin
suscept
infect
bang
warwick
found
adult
mice
princeton
pri
strain
suscept
lethal
infect
nelson
strain
mous
hepat
viru
wherea
strain
mice
resist
mate
experi
show
suscept
infect
segr
gate
singl
mendelian
domin
genet
factor
found
moreov
cultur
hepat
periton
macrophag
taken
suscept
host
support
multipl
mhv
cytopath
effect
wherea
macrophag
resist
mice
interest
observ
show
inherit
resist
properti
individu
macrophag
manifest
vitro
ab
senc
acquir
immun
respons
observ
mhv
strain
also
emphas
relationship
virul
capac
virus
multipli
macrophag
thu
avirul
strain
multipli
macrophag
wherea
viru
lent
strain
intraperiton
inject
adult
mice
strain
produc
lethal
hepat
multipli
readili
mous
periton
macrophag
giant
cell
format
fig
allison
mallucci
strain
mice
resist
infec
tion
adult
cultur
periton
macrophag
strain
show
cytopath
effect
exposur
j
l
virelizi
c
allison
unpublish
observ
parallel
inherit
resist
mice
virus
capac
mononuclear
phagocyt
support
viru
mul
tiplic
confin
murin
hepat
virus
anoth
system
analyz
detail
inherit
resist
arthropodborn
virus
b
group
sabin
found
strike
differ
suscept
hsv
pri
mice
yellow
fever
viru
determin
singl
pair
gene
resi
tanc
domin
pri
mice
also
show
mark
resist
flavivirus
resist
gener
one
type
viru
fact
pri
mice
resist
flavivirus
highli
suscept
two
resist
factor
segreg
depend
among
offspr
hybrid
kantoch
et
al
shown
goodman
koprowski
macrophag
suscept
mice
support
multipl
flavivirus
ef
ficient
wherea
macrophag
resist
mice
similar
observ
subsequ
made
koprowski
labora
tori
mice
congen
resist
gene
b
ragerzisman
c
allison
unpublish
observ
found
encephalomyocard
viru
virul
adult
mice
repli
cate
macrophag
henc
littl
doubt
capac
viru
multipli
macrophag
import
aspect
viru
lenc
cours
one
also
found
zisman
et
al
resist
weanl
mice
intraperiton
inject
herp
simplex
viru
could
broken
inject
silica
particl
rabbit
antimous
macrophag
serum
treatment
lead
rapid
mortal
begin
day
infect
high
titer
viru
liver
virusinduc
hepat
necrosi
result
expect
kupffer
cell
barrier
spread
viru
broken
contrast
antilymphocyt
serum
result
later
mortal
lower
concentr
viru
liver
hepa
titi
higher
viremia
enceph
might
expect
slow
buildup
viru
blood
owe
failur
acquir
immun
respons
secondari
spread
across
bloodbrain
barrier
observ
conclud
macrophag
im
portant
prevent
spread
virus
primari
site
infec
tion
highli
suscept
cell
liver
paren
chyma
brain
discuss
next
macrophag
newborn
anim
carri
function
ineffici
capac
contain
viru
infect
prevent
spread
suscept
cell
ture
rapidli
first
week
postnat
life
mice
allison
colleagu
analyz
role
macro
phage
barrier
spread
virus
develop
new
born
anim
experi
herp
simplex
viru
mice
use
illustr
point
probabl
appli
also
mani
virus
well
intracellular
infect
intraperiton
inocul
newborn
mice
herp
simplex
viru
follow
rapid
spread
viru
viscera
enceph
death
wherea
similar
inject
weanl
adult
mice
result
viral
spread
liver
brain
morbid
mortal
resist
intraperiton
infect
develop
rapidli
first
week
life
transfer
periton
macrophag
adult
cba
syngen
suckl
mice
abl
confer
larg
measur
protect
intraperiton
infect
herpesviru
similar
transfer
periton
lymphocyt
adult
anim
without
protect
effect
hirsch
et
al
studi
show
adult
macrophag
particularli
stimu
late
prior
inject
proteosepepton
much
ef
ficient
take
prevent
spread
viru
macro
phage
suckl
anim
whether
stimul
reflect
diminish
capac
infect
adult
macrophag
establish
infecti
center
cultur
togeth
suscept
cell
similar
find
report
johnson
addit
diminish
capac
adult
macrophag
transfer
viru
contigu
cell
variou
reason
thought
due
releas
interferon
basi
still
well
defin
adult
macrophag
may
replic
viru
less
well
macrophag
neonat
view
reinforc
studi
steven
cook
show
herp
simplex
viru
adult
mous
macrophag
undergo
abort
cycl
replic
synthesi
viru
nucleic
acid
antigen
format
nascent
capsid
lack
dens
core
nucleu
henc
late
stage
herpesviru
synthesi
perhap
involv
dna
metabol
nucleocapsid
format
appear
block
adult
mous
macrophag
human
counterpart
experi
sever
gener
aliz
infect
herp
simplex
viru
produc
newborn
children
wheeler
huffin
nahmia
et
al
usual
herpesviru
type
acquir
childbirth
matern
genit
infect
occasion
type
infect
viru
di
semin
wide
central
nervou
system
liver
organ
administr
antibodi
provid
demon
strabl
protect
great
major
children
die
immatur
macrophag
human
newborn
may
well
import
con
tributori
factor
allow
dissemin
infect
kupffer
cell
barrier
poorli
develop
human
fetus
newborn
suggest
involv
hepat
parenchym
cell
congenit
rubella
infect
seen
adult
case
rubella
stern
william
ragerzisman
allison
also
found
newborn
mice
could
protect
intraperiton
inocul
coxsacki
b
viru
syngen
adult
periton
exud
cell
presenc
small
amount
antibodi
creas
protect
effect
matur
macrophag
virucid
capac
first
week
life
may
link
cellmedi
immun
stimula
tion
bacteri
antigen
work
macka
other
suggest
lymphocytemedi
immun
respons
increas
capac
macrophag
kill
organ
unrel
provid
antigen
stimulu
report
macrophag
taken
later
neonat
thymectom
anim
support
multipl
avirul
viru
wherea
viru
multipli
limit
extent
macrophag
intact
adult
anim
work
continu
use
virul
strain
viru
genet
resist
strain
mice
suc
cumb
infect
soon
birth
neonat
thymectom
infect
adult
dupuy
et
al
levyleblond
dupuy
latter
investig
j
l
virelizi
c
allison
un
publish
observ
found
periton
macro
phage
taken
neonat
thymectom
mice
support
mul
tiplic
viru
giant
cell
format
wherea
normal
mice
age
also
txbm
mice
resi
tant
strain
test
week
thymu
depriv
resi
tant
viru
replic
observ
cultur
periton
macrophag
anim
howev
similar
mice
test
month
thymu
depriv
time
macrophag
present
probabl
develop
environ
ment
defici
lymphocyt
put
thymic
hormon
found
suscept
infect
periton
macrophag
replic
viru
vitro
macrophag
thymusdepriv
mice
gener
thought
normal
howev
observ
demonstr
least
one
properti
matur
macrophag
virucid
capac
iti
depend
presenc
thymu
andor
lymphocyt
least
develop
macrophag
func
tion
particip
granuloma
format
defici
newborn
neonat
thymectom
mice
yang
skinsn
howev
transfer
experi
macrophag
anim
necessari
conclus
made
concern
role
lymphocyt
establish
development
depend
macrophag
thymu
cell
exper
iment
demonstr
inabl
macrophag
newborn
anim
particip
immun
respons
vivo
see
hardi
et
al
reexamin
possibl
mind
mani
virus
envelop
deriv
host
cell
membran
virus
intim
relat
host
cell
membran
adsorpt
penetr
replic
lead
profound
chang
cell
membran
well
basic
physiolog
behavior
cell
relationship
environ
see
review
allison
infect
virus
result
cell
membran
alter
detect
appear
new
antigen
sometim
chang
abil
bind
particular
lectin
materi
tabl
iii
list
virus
known
produc
antigen
chang
host
membran
detect
biolog
calli
transplant
studi
directli
immunofluoresc
immunoradiolabel
immunoelectron
microscopi
assay
em
ploy
cytotox
antibodi
lymphoid
cell
note
antisera
use
mani
assay
produc
activ
infect
viru
antigen
chang
may
repres
virusinduc
host
cell
alter
antigen
structur
en
code
viru
genom
surfac
antigen
appear
earli
infect
thu
cell
infect
influenza
viru
produc
viral
protein
hour
noll
virusspecif
cell
surfac
antigen
detect
hour
infect
hahon
eckert
new
surfac
antigen
ap
pear
cell
infect
ndv
hour
vee
sindbi
virus
hour
vaccinia
viru
hour
hsv
hour
measl
rinderpest
canin
distemp
virus
hour
studi
protein
nucleic
acid
synthesi
inhibitor
demonstr
new
protein
must
synthes
antigen
detect
abl
ie
antigen
adsorb
virion
nucleic
acid
synthesi
usual
requir
thu
antigen
chang
proba
bli
repres
earli
function
viru
genom
appar
ex
ception
transplant
reject
antigen
tra
produc
infect
appear
lytic
infect
appear
late
transform
nonpermiss
cell
smith
mora
infect
virus
produc
detect
surfac
antigen
picornavirus
although
associ
cytoplasm
membran
develop
bud
membran
lack
mem
brane
envelop
perhap
significantli
regard
also
lack
carbohydr
virus
contain
carbohydr
attach
viru
protein
latter
embed
host
membran
cell
infect
coxsacki
viru
picornaviru
surfac
antigen
detect
immunofluoresc
radiolabel
hayashi
et
al
strain
vaccinia
viru
report
produc
major
surfac
antigen
normal
found
earli
infect
ito
barron
cell
transform
moloney
variant
murin
sarcoma
viru
msc
also
produc
helper
murin
leukemogen
viru
possess
surfac
antigen
specifi
latter
viru
msvtransform
cell
line
produc
helper
viru
avail
strouk
et
al
could
detect
virusspecif
surfac
antigen
klein
geer
et
al
aoki
et
al
shirai
et
al
stockert
et
al
proffitt
et
al
nishioka
et
al
oshiro
et
al
boon
et
al
gelderblom
et
al
kurth
bauer
gelderblom
bauer
phillip
perdu
ducnguyen
et
al
brier
et
al
hahon
eckert
ducnguyen
rosenblum
speel
et
al
eaton
scala
holm
et
al
yamanouchi
et
al
rustigian
et
al
labowski
et
al
epsmark
mantani
hahon
catanzaro
et
al
pfefferkorn
mcfarland
catanzaro
et
al
fernand
et
al
wiktor
et
al
lundstedt
oldston
et
al
wright
et
al
marker
volkert
zinkernagel
doherti
alford
vasconceloscosta
vasconceloscosta
et
al
odea
dineen
roan
roizman
epsmark
nii
et
al
brier
et
al
lowri
et
al
nahmia
et
al
ito
barron
smith
et
al
gershon
et
al
langenhuysen
klein
et
al
dunkel
zeigel
chen
purchas
miyamoto
kato
ueda
et
al
brier
et
al
hayashi
et
al
ito
barron
ishimoto
ito
tompkin
et
al
smith
et
al
ting
herberman
wright
law
kedar
et
al
irlin
malmgren
et
al
ting
herberman
key
ct
antibodi
complement
cytotox
ia
immun
adher
iem
immunoelectron
microscopi
immunofluoresc
lc
lymphocytemedi
cyto
toxic
ri
radioimmunoassay
cell
use
hemadsorpt
lymphocyt
cytotox
assay
stephenson
aaronson
fail
detect
transplanta
tion
antigen
similar
cell
line
law
ting
find
transplant
antigen
issu
settl
virusinduc
surfac
antigen
thought
viru
code
found
virion
gross
leukemogen
viru
produc
varieti
antigen
infect
cell
among
nonvirion
surfac
antigen
gcsaa
gcsab
similarli
transplant
antigen
adenovirus
polyoma
viru
identifi
virion
recogniz
new
surfac
antigen
probabl
result
un
mask
antigen
substructur
alreadi
present
derepress
host
gene
cell
hamster
kidney
line
bhk
normal
demonstr
forssman
antigen
acquir
transforma
tion
polyoma
viru
rou
sarcoma
viru
fogel
sach
oneil
robertson
black
appear
transform
cell
access
receptor
lectin
glycoprotein
plant
invertebr
capabl
agglu
tinat
certain
cell
bind
particular
carbohydr
may
also
repres
unmask
phenomenon
rearrang
mem
brane
compon
burger
review
subject
ap
pear
lectin
receptor
normal
transform
cell
may
present
equal
amount
viru
transform
mild
treatment
normal
cell
proteas
lead
directli
cluster
lectinbind
receptor
increas
mobil
lectinbind
site
cluster
presenc
multival
lectin
rosenblith
et
al
even
demonstr
chang
concentr
membran
compon
relat
enzym
transforma
tion
process
bradi
et
al
sialic
acid
level
found
reduc
wu
et
al
polyoma
viru
ohta
et
al
transform
cell
compar
parent
cell
usual
reduct
higher
gangliosid
homologu
well
bradi
mora
higher
gangliosid
form
sequen
tial
addit
variou
hexos
moieti
sialic
acid
mediat
transferas
enzym
examin
one
transferas
involv
reveal
markedli
reduc
polyoma
viru
transform
cell
bradi
et
al
viral
alter
en
zyme
concern
membran
biosynthesi
structur
gangliosid
transferas
might
alter
phenotyp
express
much
way
lysogen
convers
salmonella
e
phage
robbin
uchida
appear
cell
infect
hsv
receptor
bind
fc
portion
rabbit
human
igg
molecul
report
yasuda
milgrom
shimizu
westmoreland
watkin
fc
receptor
appear
surfac
infect
cell
test
includ
fibroblast
epith
lial
cell
mice
hamster
monkey
human
receptor
ap
pear
hela
cell
within
hour
infect
hour
infect
estim
x
molecul
igg
per
cell
bound
cell
membran
minut
experi
actinomycin
puromycin
suggest
earli
need
rna
syn
thesi
infect
continu
synthesi
receptor
evid
obtain
suggest
unmask
fc
receptor
alreadi
present
cryptic
form
antisera
uninfect
host
cell
hsv
block
subsequ
attach
immunoglobulin
infect
cell
could
due
steric
hindranc
fc
receptor
might
contain
host
viral
antigen
determin
viral
protein
glycosyl
host
enzym
function
fc
ceptor
could
characterist
known
whether
viru
code
protein
receptor
glycosyl
cellular
enzym
resembl
fc
receptor
known
present
macrophag
neutrophil
b
lymphocyt
possibl
lymphocyt
altern
infect
could
result
derepress
appropri
host
gene
control
syn
thesi
receptor
latter
possibl
intrigu
view
recent
suggest
fc
receptor
product
ir
gene
complex
sinc
gene
control
immun
respons
infec
tion
lymphocyt
virus
activ
gene
complex
might
affect
immun
respons
perhap
permit
autoimmun
respons
viru
infect
result
appear
n
e
w
host
antigen
also
diminut
normal
membran
tigen
hecht
summer
found
reduct
capac
vsvinfect
mous
cell
adsorb
cytolyt
antibodi
direct
antigen
due
inhibit
pro
tein
synthesi
treatment
cell
cycloheximid
similar
time
period
reduc
concentr
infect
encephalomyocard
viru
inhibit
host
protein
synth
si
whether
cell
antigen
particularli
tumor
antigen
behav
similarli
infect
merit
examin
least
one
tumor
antigen
known
cocap
thu
link
tigen
conceiv
may
alter
factor
influenc
densiti
good
edidin
recent
hecht
summer
report
ndvinfect
l
mous
cell
lose
antigen
polar
redistribut
cap
surfac
immunoglobulin
taylor
et
al
receptor
immun
complex
lymphocyt
transplant
antigen
varieti
cell
type
kourilski
et
al
report
mani
laboratori
much
specul
concern
physiolog
im
portanc
arisen
joseph
describ
cap
ping
measl
viru
antigen
infect
hela
cell
requir
ac
tive
cell
metabol
multival
antibodi
cap
also
observ
mump
antigen
infect
cell
k
hayashi
per
sonal
commun
antigen
gross
virusinduc
leukem
cell
yoshiki
et
al
may
gener
phenomenon
virusspecif
cell
surfac
antigen
cap
viral
antigen
surfac
infect
cell
could
number
consequ
viral
nucleocapsid
must
align
beneath
membran
contain
viral
protein
bud
ding
eg
myxovirus
cap
could
interfer
viral
mor
phogenesi
releas
alter
densiti
viral
antigen
cell
surfac
might
result
ineffect
interact
cell
lymphocyt
attach
antibodi
com
plement
brier
et
al
nonlyt
infect
thu
protect
effect
immun
respons
might
persist
phenomenon
similar
cap
result
revers
loss
surfac
antigen
term
antigen
modul
also
occur
host
antigen
tl
thymusleukemia
antigen
mice
organspecif
allotyp
determin
thymocyt
certain
mous
strain
genet
locu
near
end
locu
boys
et
al
boys
old
leukemia
induc
leukemogen
virus
tlposit
mous
strain
result
appear
tl
antigen
leukem
cell
leukem
cell
tran
plant
tlneg
anim
previous
immun
tl
tigen
produc
antibodi
antigen
quickli
lost
cell
surfac
reappear
leukem
cell
tran
plant
back
tlposit
host
lack
antibodi
tl
phenotyp
express
tl
found
markedli
reduc
demonstra
ble
quantiti
antigen
especi
specifi
region
loss
tl
antigen
modul
increas
antigen
observ
tigen
modul
gcsaa
antigen
leukem
cell
appear
code
gross
leukemia
viru
rather
host
also
report
recent
experi
zinkernagel
doherti
rais
interest
possibl
virusinduc
surfac
antigen
may
combin
viru
host
materi
investig
port
lymphocyt
lcminfect
mice
capabl
mediat
cytotox
reaction
infect
target
cell
share
similar
either
k
region
locu
reactiv
lymphocyt
sensit
complement
thu
lymphocyt
mention
found
requir
similar
system
r
v
blanden
person
commun
obtain
similar
result
use
ectromelia
viru
one
explan
phenomenon
teract
cytotox
lymphocyt
somat
cell
requir
intim
contact
strongli
depend
degre
histocompat
suggest
interact
helper
lym
phocyt
b
lymphocyt
katz
et
al
b
altern
explan
immun
lymphocyt
recogn
composit
antigen
consist
viru
protein
materi
viru
infect
result
alter
antigen
longer
recog
nize
lymphocyt
self
past
coupl
decad
knowledg
structur
tibodi
protect
patholog
role
immun
well
defin
current
much
interest
center
stand
lymphoid
cell
cellmedi
immun
variou
method
use
illustr
presenc
cellmedi
immun
virusspecif
antigen
advan
tage
limit
although
delay
hypersensit
mani
virus
viral
antigen
demonstr
must
terpret
caution
exampl
reaction
elicit
antigen
heterolog
cell
virus
grown
tibodymedi
reaction
replic
antigen
may
maxim
hour
intraderm
inocul
even
histolog
may
ambigu
vitro
test
cellmedi
immun
product
correl
better
delay
hypersen
sitiv
blast
transform
david
schlossman
rocklin
et
al
peptid
tobacco
mosaic
viru
glucagon
delay
skin
reaction
correl
product
mif
lymphoid
cell
vitro
alway
stimul
dna
synthesi
exposur
host
lymphocyt
tigen
spider
et
al
senyk
et
al
seem
mif
product
particularli
good
vitro
correl
delay
hyper
sensit
guinea
pig
attempt
obtain
mif
product
cell
speci
includ
man
easili
reproduc
laboratori
mani
studi
lymphocyt
stimul
virus
per
form
part
inadequ
con
troll
exclud
possibl
involv
host
cell
antigen
character
particip
cell
manner
antigen
presen
tationwheth
infect
cell
viru
infecti
inactiv
determin
type
extent
respons
obtain
blastogen
respons
primarili
repres
antigen
recognit
lymphocyt
gershon
et
al
found
lymphocyt
may
correl
develop
recogn
lymphocyt
function
lymphocyt
cytotox
assay
repres
eifector
function
well
antigen
recognit
bach
et
al
may
complic
factor
immun
complex
influ
enc
either
function
consid
cellmedi
immun
anim
complex
multicompon
phenomenon
involv
function
dif
ferent
lymphocyt
popul
well
macrophag
k
cell
antibodi
solubl
mediat
factor
obvious
assay
one
compon
process
vitro
rather
artifici
vitro
assay
must
interpret
caution
even
investig
use
gener
begin
emerg
sensit
lymphocyt
viru
infect
earli
event
demonstr
day
infect
reach
peak
cy
totox
reactiv
day
fall
near
background
level
popul
memori
cell
cytotox
abl
gener
cytotox
eifector
cell
persist
week
month
find
stimul
dna
synthesi
lymphocyt
presenc
viru
antigen
necessarili
impli
lympho
cyte
sensit
especi
secondari
respons
b
lym
phocyt
prolifer
may
predomin
section
consid
larg
subject
outlin
form
evid
delay
hypersensit
dh
viru
antigen
briefli
mention
vitro
correl
summar
von
pirquet
suggest
hypersensit
contribut
local
inflammatori
lesion
primari
vaccinia
vaccinia
viru
continu
use
studi
dh
broom
demon
strate
human
prevaccin
lesion
occur
ab
senc
specif
antibodi
turk
et
al
inject
virusantiserum
mixtur
produc
typic
dh
reaction
guinea
pig
without
demonstr
humor
antibodi
allison
could
pa
sive
transfer
dh
vaccinia
inbr
guinea
pig
peri
toneal
exud
cell
serum
pincu
flick
use
antimononuclear
cell
antisera
inhibit
local
vaccinia
skin
lesion
guinea
pig
vitro
studi
shown
lymphoid
cell
human
im
muniz
vaccinia
respond
specif
antigen
challeng
gener
mif
tompkin
et
al
spleen
peripher
blood
lymphocyt
vacciniainfect
rabbit
expos
uvinactiv
vaccinia
found
incorpor
thirti
time
much
thymidin
dna
appropri
con
trol
rosenberg
et
al
stimul
observ
least
day
infect
peak
sec
ond
week
infect
elfenbein
rosenberg
sub
sequent
shown
b
lymphocyt
particip
prolifer
use
heatinactiv
vaccinia
viru
epstein
et
al
demonstr
transform
interferon
product
human
lymphocyt
immun
donor
poxviru
mice
crossreact
vaccinia
viru
pro
duce
sever
often
fatal
diseas
fenner
show
allerg
compon
measur
swell
foot
challeng
live
viru
variou
time
primari
infect
allergi
first
seen
seventh
day
increas
mag
nitud
thereaft
sinc
gener
infect
skin
occur
sixth
day
fenner
consid
unlik
allergi
play
import
part
local
viru
skin
howev
recent
studi
blanden
blanden
defind
role
cellmedi
immun
viru
vivo
gardner
et
al
use
chromiumreleas
cellmedi
cytotox
assay
infect
l
cell
target
cell
studi
gener
immun
lymphocyt
infect
mous
spleen
cell
show
cytotox
activ
day
immun
activ
peak
day
declin
low
level
day
activ
diminish
remov
macrophag
addit
antisera
ectromelia
exogen
interferon
abrog
prior
treatment
lymphocyt
anti
tibodi
complement
thu
mediat
lymphocyt
inocul
skin
adult
domest
rabbit
pox
viru
induc
rapidli
grow
tumor
subsequ
regress
intraderm
challeng
viru
fifth
day
produc
dh
reac
tion
allison
allison
friedman
vitro
produc
tion
mif
also
elicit
lymphocyt
obtain
day
viru
inocul
tompkin
et
al
hsv
elicit
h
reaction
larg
proport
adult
lower
proport
children
nagler
rose
molloy
anderson
kilbourn
h
hsv
guinea
pig
dem
onstrat
brown
later
lausch
et
al
show
h
could
induc
singl
inject
infect
hsv
skin
reaction
elicit
solubl
antigen
anderson
kil
bourn
jawetz
et
al
jawetz
et
al
recent
roger
et
al
demonstr
h
induc
guinea
pig
solubl
antigen
interest
determin
h
duce
andor
elicit
glycoprotein
recent
shown
neutral
antigen
hsv
cohen
et
al
powel
et
al
vitro
studi
demonstr
inactiv
hsv
stimul
dna
synthesi
sensit
lymphocyt
rosenberg
et
al
differenti
type
type
viru
rosenberg
et
al
gerber
luca
shown
peripher
blood
lym
phocyt
previous
infect
subject
stimul
incorpo
rate
thymidin
uvinactiv
eb
viru
wherea
lymphocyt
seroneg
subject
stimul
alreadi
note
variou
vitro
test
purport
demonstr
cellmedi
immun
may
depend
crucial
manner
antigen
present
may
reflect
differ
function
lymphocyt
former
point
well
demonstr
report
thurman
et
al
concern
mif
product
transforma
tion
lymphocyt
cmvinfect
patient
exposur
lymphocyt
viru
virusinfect
cell
lymphocyt
cmvinfect
patient
respond
product
mif
cultur
purifi
viru
transform
cultur
cmvinfect
cell
line
virusspecif
antigen
virion
surfac
membran
infect
cell
probabl
differ
quantita
tive
qualit
may
elicit
differ
lymphocyt
respons
stimul
differ
lymphocyt
popul
beveridg
burnet
found
skin
hypersensit
h
type
influenza
viru
interestingli
state
live
attenu
viru
administ
intranas
effect
duce
skin
hypersensit
kill
viru
vaccin
inject
subcutan
mice
inocul
inactiv
influenza
viru
devel
ope
cellmedi
immun
shown
vitro
test
feinston
et
al
hellman
et
al
report
stimul
influenza
viru
thymidin
incorpor
spleen
cell
sensi
tize
mice
begin
day
infect
peak
day
declin
f
assay
employ
wetherbe
demonstr
system
cellmedi
respons
guinea
pig
infect
intranas
influenza
viru
gadol
et
al
compar
mif
product
lymphocyt
bronchial
wash
spleen
guinea
pig
infect
intranas
footpad
rout
intranas
infect
led
mif
product
predominantli
lung
lymphocyt
wherea
parenter
inocul
result
mainli
sy
temic
immun
u
p
viru
ender
et
al
demonstr
dermal
hypersensit
mump
viru
posit
reaction
relat
immun
dh
produc
guinea
pig
mump
viru
glasgow
morgan
speel
et
al
show
spleen
cell
mice
immun
mump
viru
toxic
chang
cell
persi
tentli
infect
mump
lymphocyt
mice
infect
mump
viru
shown
produc
mif
vitro
feinston
et
al
use
inactiv
mump
viru
smith
et
al
demonstr
stimul
dna
synthesi
human
lymphocyt
primari
exposur
year
primari
exposur
correl
delay
skin
sensit
skin
test
measl
viru
complic
contami
nate
antigen
deriv
cell
use
cultur
viru
isacson
number
vitro
assay
employ
assess
cellmedi
immun
measl
viru
close
relat
agent
subacut
scleros
panenceph
sspe
colonyinhibit
assay
use
lymphocyt
monkey
infect
measl
viru
cell
persist
infect
viru
rustigian
et
al
labowski
et
al
report
lym
phocyt
seroposit
individu
capabl
morpho
logic
destruct
lysi
cell
line
persist
infect
measl
reaction
could
block
pretreat
target
cell
antisera
measl
thurman
et
al
ahm
et
al
report
lymphocyt
seroposit
individu
produc
f
lymphotoxin
exposur
purifi
measl
viru
interestingli
blastogen
respons
occur
exposur
lymphocyt
viru
prepar
cmv
elicit
lymphocyt
cultur
virusinfect
cell
much
controversi
concern
natur
cellmedi
immun
gener
measl
antigen
viru
particular
patient
subacut
scleros
panenceph
report
diminish
lymphocyt
respons
pha
kolar
lack
normal
dermal
hypersensit
reaction
common
test
antigen
well
delay
reject
skin
allograft
gerson
haslam
howev
jabbour
et
al
found
eight
patient
test
normal
skin
respons
candida
two
three
patient
could
sensit
dichloronitrobenzen
j
f
soothil
privat
commun
found
normal
lym
phocyt
respons
pha
eight
case
normal
vitro
cellmedi
immun
antigen
measl
report
twenti
case
moulia
et
al
gener
defect
cellmedi
immun
therefor
establish
two
report
five
patient
sspe
confirm
normal
reactiv
lymphocyt
sspe
patient
f
lymphotoxinreleas
assay
use
viru
prepar
measl
sspe
agent
antigen
transform
assay
use
sspeinfect
cell
stimul
ahm
et
al
block
factor
found
high
concentr
cerebrospin
fluid
sspe
patient
lesser
concentr
sera
found
block
reaction
lymphocyt
sspe
patient
normal
seroposit
individu
mif
lymphotoxinreleas
tran
format
assay
specif
sspe
agent
antigen
ahm
et
al
factor
heatlabil
larger
mw
sensit
action
trypsin
neuraminidas
neutral
rheumatoid
factor
may
tigenantibodi
complex
use
lymphocytemedi
cytotox
assay
labowski
et
al
j
bellanti
colleagu
person
commun
confirm
normal
reactiv
lymphocyt
seven
sspe
patient
measlesinfect
cell
worker
also
found
specif
block
factor
sera
patient
con
clusion
appear
sspe
patient
capac
mount
cellmedi
immun
respons
gener
measlesssp
viru
antigen
particular
reaction
latter
thwart
block
factor
possibl
immun
complex
found
pre
dominantli
csf
cellmedi
respons
murin
leukemia
recog
nize
year
howev
congenit
infect
murin
leu
kemia
virus
formerli
thought
result
toler
viru
antigen
recent
circul
antibodi
virus
demonstr
concept
split
toler
humor
respons
accompani
cellmedi
respons
suggest
recent
proffitt
et
al
pre
sent
evid
cellmedi
immun
carrier
mice
moloney
leukemia
viru
lymphocyt
anim
mediat
cytotox
reaction
syngen
cell
infect
moloney
leukemia
viru
uninfect
cell
wahren
metcalf
report
similar
result
use
carrier
mice
mo
loney
mulv
embryo
cell
cultur
mice
target
cell
lymphocyt
normal
mice
cytotox
target
cell
latter
investig
also
report
cytotox
reaction
lymphocyt
preleukem
akr
mice
cell
monolay
akr
embryo
akr
thymic
epitheli
cell
mani
tissu
akr
mice
known
possess
gross
mulv
antigen
target
cell
probabl
possess
viral
antigen
sinc
cyto
toxic
reaction
prevent
pretreat
target
cell
antisera
gross
cell
surfac
antigen
varianc
studi
chiecobianchi
et
al
report
cytotox
reac
tion
spleen
lymphocyt
adult
mice
fect
neonat
moloney
mulv
syngen
moloney
mulvinfect
target
cell
differ
product
viru
carrier
state
cytotox
assay
employ
may
account
discrep
last
studi
chromiumreleas
assay
use
previou
studi
microcytotox
assay
similar
coloni
inhibit
assay
use
import
differ
assay
known
bieseck
et
al
bloom
et
al
begin
day
footpad
inocul
mice
sindbi
viru
lymphocyt
drain
node
spleen
un
derwent
blastogenesi
exposur
viru
griffin
johnson
sensit
peak
day
infect
turn
control
level
day
lysi
infect
syngen
mous
embryo
cell
immun
lymphocyt
follow
similar
slightli
shorter
time
cours
mcfarland
latter
function
sensit
treatment
antisera
complement
thu
probabl
repres
lymphocyt
activ
stimul
spleen
lymphocyt
immun
mice
vene
zuelan
equin
enceph
viru
vee
report
adler
rabinowitz
reactiv
lymphocyt
mice
ceiv
one
immun
dose
viru
abolish
treatment
sera
complement
lymphocyt
mice
receiv
two
immun
dose
reactiv
latter
lymphocyt
sensit
treatment
antisera
mous
immunoglobulin
plu
complement
result
suggest
primari
immun
antigen
recognit
prolifer
immun
spleen
cell
popul
due
lymphocyt
secondari
immun
reactiv
cell
predominantli
b
lymphocyt
find
agreement
elfen
bein
rosenberg
vaccinia
viru
chromiumreleas
assay
use
persist
infect
bhk
cell
describ
peripher
blood
lymphocyt
seroposit
subject
cytotox
assay
steel
et
al
smith
et
al
describ
assay
measur
bla
togen
respons
human
lymphocyt
exposur
rubella
antigen
use
similar
assay
lee
sigel
examin
influenc
immun
complex
blastogen
respons
blood
lymphocyt
immun
rabbit
exposur
inac
tivat
rubella
viru
respons
alter
presenc
complex
viru
antirubella
igg
viru
complex
antirubella
igm
markedli
inhibitori
normal
igm
mix
rubella
viru
antirubella
igm
mix
polioviru
influenza
viru
effect
studi
hsv
rosenberg
et
al
hyperimmun
sera
mix
hsv
inhibit
blastogenesi
antihsv
antibodi
sera
probabl
igg
class
examin
effect
immun
respons
virusantibodi
complex
attent
antibodi
class
especi
inter
est
measl
viru
sspe
agent
consider
evid
vivo
cellmedi
respons
infect
adult
rodent
lcm
viru
lehmanngrub
cole
exampl
tosolini
mim
describ
time
cours
develop
h
reaction
acut
fect
mice
use
footpad
test
vitro
assay
employ
persist
infect
l
cell
target
cell
immun
lymphocyt
benson
first
show
immun
spleen
lymphocyt
inhib
ite
adher
growth
infect
l
cell
phenom
enon
studi
detail
lundstedt
similar
studi
demonstr
cytotox
effect
immun
lymphocyt
em
ploy
hellstrom
method
wright
et
al
chromiumreleas
assay
oldston
et
al
marker
volkert
zinkernagel
doherti
demonstr
immun
lymphocyt
respons
specif
cytotox
sensit
antisera
complement
effector
activ
appear
day
infect
peak
day
fall
sharpli
offa
pattern
similar
infect
ectromelia
viru
sindbi
viru
recent
report
three
laboratori
indic
immun
spleen
cell
obtain
earli
infect
differ
late
immun
spleen
cell
mim
blanden
johnson
et
al
volkert
et
al
former
cell
addit
cytotox
vitro
assay
possess
antivir
activ
protect
mice
acut
lethal
infect
late
immun
cell
lack
properti
acut
infect
mice
strong
antivir
activ
tran
plant
chronic
infect
mice
situat
earli
im
mune
cell
littl
effect
also
cytotox
antivir
activ
earli
immun
cell
rel
resist
xirradi
antivir
activ
transfer
chronic
infect
mice
late
immun
cell
radiat
sensit
function
popu
lation
cell
sensit
treatment
antisera
complement
thu
lymphocyt
involv
popula
tion
perhap
late
immun
cell
compris
rel
activ
cytotox
lymphocyt
mani
memori
lymphocyt
ca
pabl
period
time
longer
involv
acut
infec
tion
produc
larg
popul
cytotox
cell
lifelong
immun
reinfect
produc
mani
virus
includ
smallpox
poliomyel
yellow
fever
acut
childhood
exanthema
panum
show
faro
island
success
measl
epidem
separ
interv
year
epidem
infect
previous
expos
spare
ex
pose
report
antibodi
persist
absenc
reinfect
includ
yellow
fever
viru
year
sawyer
poliomyel
among
eskimo
year
paul
et
al
rift
valley
fever
year
sabin
blumberg
reexposur
viru
may
increas
durat
immun
thu
krugman
et
al
found
rise
neutral
antibodi
titer
immun
subject
expos
measl
similar
observ
made
vaccin
subject
expos
smallpox
downi
mccarthi
two
explan
put
forward
prolong
antivir
immun
absenc
reinfect
accord
one
persist
specif
clone
immunocompet
cell
burnet
accord
persist
viru
olitski
long
b
observ
antibodi
rabbit
year
innocul
inactiv
polioviru
svehag
similar
data
man
administr
kill
viru
vaccin
show
immunologi
memori
exist
whether
explain
lifetim
antibodi
product
absenc
antigen
stimul
uncertain
mani
virus
known
persist
infect
olitski
long
suggest
immun
viru
diseas
may
link
persist
bodi
live
viru
de
koch
found
blood
hors
recov
attack
equin
pernici
anemia
infecti
year
later
salivari
gland
viru
guinea
pig
could
recov
time
infect
presenc
antibodi
cole
kuttner
vaccinia
viru
isol
rabbit
month
inocul
olitski
long
b
measl
viru
isol
brain
lymph
node
patient
subacut
scleros
panenceph
horta
barbosa
et
al
payn
et
al
lymph
node
spleen
normal
subject
year
fection
endersruckl
adenovirus
commonli
isol
human
tonsillar
adenoid
tissu
israel
strohl
schlesing
rabbit
persist
long
period
splenic
lymph
node
cell
pereira
kelli
reddick
lefkowitz
allison
faucon
et
al
mous
cytomegalovirus
isol
spleen
lymph
node
chronic
infect
mice
henson
et
al
virus
lymphocyt
choriomening
viru
lactat
dehydrogenas
viru
often
persist
lifetim
host
anim
even
presenc
antibodi
human
herpesvirus
well
known
latenc
tendenc
establish
recur
infect
human
cmv
often
isol
leukocyt
normal
person
diosi
et
al
perham
et
al
lang
eb
viru
may
induc
lym
phocyt
year
recoveri
infecti
mononucleosi
diehl
et
al
varicellazost
viru
remain
dormant
year
chicken
pox
reappear
clinic
zoster
initi
hsv
infect
present
childhood
stomat
subsequ
posit
titer
c
f
neutral
antibodi
yoshino
et
al
hsv
later
isol
asymptomat
subject
well
herpet
lesion
buddingh
et
al
kaufman
et
al
year
ago
goodpastur
suggest
viru
remain
dormant
state
recurr
sensori
ganglia
direct
proof
concept
lack
recent
steven
cook
isol
hsv
spinal
ganglia
mice
week
recoveri
posterior
paralysi
follow
viru
inocul
hind
footpad
rabbit
trigemin
ganglia
month
recov
eri
corneal
infect
steven
et
al
viru
recov
ganglia
prox
imal
distal
nerv
structur
except
acut
infect
viru
could
detect
ganglia
electron
microscopi
fectiou
viru
assay
ganglia
explant
cultur
period
time
vitro
could
viru
recov
recov
eri
hsv
vitro
cultur
human
trigemin
ganglia
ob
tain
autopsi
patient
without
activ
herp
infect
report
bastian
et
al
baring
swoveland
j
r
baring
recent
isol
type
genit
herp
sacral
ganglia
human
appear
viru
activ
explant
cultur
probabl
due
metabol
chang
neuron
subsequ
injuri
rather
remov
tissu
environ
free
immun
respons
interpret
consist
find
hsv
ac
tivat
dorsal
ganglia
sciatic
nerv
injuri
walz
et
al
wellknown
observ
proxim
rhizotomi
human
trigemin
ganglion
result
activ
hsv
cush
carton
kilbourn
work
traub
show
mous
coloni
vertic
transmiss
mother
offspr
lymphocyt
choriomening
lcm
viru
establish
symptomless
lifelong
infect
antivir
antibodi
demonstr
cir
culat
blood
infect
adult
mice
lcm
lead
immunopatholog
diseas
antibodi
format
lack
antibodi
congenit
lcm
viru
infect
one
observa
tion
led
burnet
fenner
postul
exist
immunologi
toler
recent
oldston
dixon
benson
hotchin
demonstr
mice
congenit
infect
lcm
viru
presenc
antivir
antibodi
accumul
kidney
immun
complex
contain
viral
antigen
antibodi
oldston
dixon
henc
congenit
infect
mice
abl
make
antibodi
viral
antigen
volkert
hannoverlarsen
found
spleen
cell
lcmimmun
mice
infect
adult
tran
fer
syngen
congenit
infect
carrier
anim
high
level
antibodi
form
immunopatholog
diseas
result
simplest
interpret
find
appear
lcm
viral
antigen
produc
toler
resembl
occur
autoantigen
low
dose
name
lymphocyt
specif
viral
antigen
becom
unrespons
specif
b
lymphocyt
remain
abl
respond
antigen
allison
absenc
specif
helper
cell
small
amount
antibodi
produc
combin
antigen
liber
circul
form
immun
complex
accumul
kidney
lead
eventu
alli
immunopatholog
glomerulonephr
howev
virusspecif
cell
suppli
adopt
immun
helper
effect
greatli
increas
antibodi
format
recipi
helper
role
cell
antibodi
format
lcm
viral
tigen
demonstr
experi
cole
et
al
adopt
immun
congenit
infect
lcm
viru
carrier
mice
spleen
cell
syngen
immun
donor
result
high
antibodi
level
alreadi
describ
treatment
spleen
cell
serum
transfer
virtual
abolish
effect
thu
even
presenc
b
cell
immun
donor
littl
antibodi
form
unless
sensit
cell
also
present
interpret
experi
complic
fact
recipi
level
viru
reduc
antigen
load
less
chanc
find
free
antibodi
increas
howev
level
antibodi
recipi
high
unlik
whole
explan
long
time
thought
mice
congenit
infect
leukemogen
virus
would
likewis
toler
virusspecif
tigen
howev
aoki
et
al
detect
antibodi
gross
leuk
mogen
viru
cell
surfac
antigen
gcsa
sera
old
mice
mellor
et
al
found
gross
solubl
tigen
mixtur
virusspecif
antigen
creas
sera
nzb
mice
month
age
increas
titer
antibodi
antigen
could
detect
immun
elimin
viral
antigen
occur
glomerulonephr
progress
renal
eluat
contain
antibodi
gross
solubl
antigen
mellor
et
al
previous
prepar
mice
antisera
gross
viru
result
product
antibodi
gcsa
neutral
antibodi
direct
virion
envelop
antigen
gvea
led
hypothesi
due
occult
infect
earli
life
mice
might
toler
vea
howev
old
nzb
mice
found
make
natur
tibodi
gvea
recent
yoshiki
et
al
report
nzb
nzw
fj
hybrid
mice
contain
remark
high
concentr
viral
envelop
glycoprotein
protein
deposit
immun
complex
glomeruli
mice
much
greater
concentr
major
structur
protein
virion
studi
highleukem
akr
mous
strain
also
provid
evid
antibodi
respons
endogen
infect
gross
leukemogen
viru
report
glomerulonephr
develop
spontan
akr
mice
renal
eluat
contain
antibodi
gcsa
complementfix
antibodi
intern
viral
compon
use
immunofiuoresc
markham
et
al
found
igg
antibodi
complement
along
viral
antigen
kidney
akr
mice
holli
et
al
elut
akr
mous
kidney
igm
igg
antibodi
direct
virion
revers
transcriptas
expect
antibodi
react
mous
felin
avian
revers
transcriptas
much
antibodi
akr
viru
antigen
found
glomeruli
may
direct
viral
antigen
produc
situ
infect
cell
especi
mesangi
cell
pascal
et
al
yoshiki
et
al
strain
mice
also
produc
natur
antibodi
gross
viral
antigen
thu
lowleukem
rf
mice
mice
porter
et
al
produc
antivir
antibodi
develop
chronic
glomerulonephr
half
antibodi
elut
kidney
latter
mice
year
age
react
gcsa
predominantli
igm
antibodi
gvea
also
detec
sera
glomeruli
mice
well
balbc
akr
mice
ihl
et
al
batz
et
al
use
sensit
radioimmun
precipit
assay
serum
react
isotop
label
viru
complex
form
precipit
appropi
antiglobulin
antibodi
gvea
mainli
igg
detect
sera
inbr
mous
strain
stud
i
nowinski
kaehler
antigen
character
virion
envelop
glycoprotein
recent
lee
et
al
examin
sera
normal
mice
found
antibodi
react
antigen
compon
gross
second
viral
env
lope
glycoprotein
mw
dalton
small
viru
core
protein
antibodi
fraction
react
nonenvelop
protein
antibodi
neutral
xenotrop
balb
crossreact
gross
viru
vide
infra
humor
respons
also
made
vertic
transmit
murin
oncornavirus
hirsch
et
al
branca
et
al
found
mice
congenit
infect
moloney
leukemogen
sarcoma
virus
complex
viral
antigen
antibodi
glomeruli
recent
endogen
murin
oncornavirus
leas
spontan
cell
balbc
nzb
mice
unabl
grow
mous
cell
abl
grow
cell
speci
thu
call
xenotrop
virus
isol
design
balb
nzbmulv
respect
neutral
ize
antibodi
two
virus
crossreact
wide
spread
present
high
titer
mice
strain
test
except
nih
strain
aaronson
stephenson
investig
suggest
previou
studi
detect
natur
antibodi
gross
viral
antigen
may
primarili
direct
balb
class
endogen
virus
crossreact
lower
level
grosstyp
viru
crossreact
balb
gross
leukemogen
viru
exist
sinc
antisera
latter
viru
neutral
former
normal
balbc
sera
neutral
balb
neu
traliz
virus
gross
fmr
subgroup
antigen
rela
tionship
virus
await
clarif
anoth
xenotrop
viru
isol
athym
nude
mice
neutral
tibodi
viru
mainli
igm
detect
high
titer
nude
mice
viru
isol
sera
also
neu
traliz
balb
nzbmulv
cross
h
mors
j
hartley
person
commun
mice
infect
utero
neonat
inherit
viral
genom
mendelian
chromosom
fashion
make
antibodi
respons
viral
antigen
thu
toler
antigen
classic
sens
whether
also
mount
cellmedi
immun
respons
viral
antigen
less
clear
recent
proffitt
et
al
found
lymphocyt
carrier
mice
carri
moloney
leukemogen
viru
cytotox
cell
bear
virusspecif
antigen
reaction
mediat
lymphocyt
lack
toler
suggest
similar
observ
gross
leuk
mogen
viru
mulvg
publish
wahren
metcalf
absenc
toler
mice
neonat
infect
polyoma
viru
found
allison
lymphocyt
anim
abl
protect
immunosuppress
recipi
polyoma
tumor
format
mani
investig
describ
lymphocytemedi
cytotox
cell
cultur
lcm
viru
replic
vide
supra
observ
mice
infect
lcm
viru
adult
carrier
mice
infect
newborn
support
view
carrier
mice
lympho
cyte
reactiv
virusspecif
antigen
necessarili
antigen
enter
circul
blood
studi
suggest
difficult
induc
toler
virusspecif
antigen
formerli
suppos
although
exampl
select
toler
eg
specif
induc
unrespons
lympho
cyte
congenit
lcm
infect
appear
exist
yet
known
whether
due
delet
inactiv
lympho
cyte
temporari
inhibit
respons
antigen
im
mune
complex
exampl
respons
strong
immunogen
increas
respons
second
weaker
immunogen
coupl
extens
studi
especi
carrier
effect
hapten
coupl
differ
carrier
protein
katz
benacerraf
leskowitz
analog
way
presenc
highli
immunogen
chicken
isoantigen
b
along
weaker
isoantigen
cell
elicit
stronger
normal
immun
respons
latter
schierman
mcbride
conceiv
highli
immunogen
viral
coat
protein
may
increas
respons
less
immunogen
compon
tumor
transplant
antigen
often
weakli
immunogen
immunogen
variou
tumor
improv
associ
tumor
antigen
stronger
immunogen
form
somat
hybrid
antigen
cell
watkin
chen
viru
infect
review
lin
denmann
thu
lindenmann
klein
prepar
viral
oncolys
infect
ehrlich
ascit
tumor
cell
influenza
viru
show
immun
mice
prepar
would
protect
lethal
dose
uninfect
tumor
cell
eleven
day
later
even
inactiv
partial
purifi
viru
oncolys
protect
indic
direct
viral
lysi
tumor
vivo
involv
antisera
viru
prepar
influenza
viru
grown
egg
elimin
protect
ef
fect
simpl
mixtur
viru
tumor
cell
effect
indic
close
coupl
viral
tumor
antigen
requir
find
confirm
halonen
sinc
virion
rigor
purifi
oncolysi
decid
experi
whether
immunogen
fragment
cell
membran
contain
viru
tigen
virion
contain
host
materi
latter
interpret
favor
similar
experi
vsv
fowlplagu
viru
viral
oncolys
immunogen
prepar
follow
appear
progeni
viru
long
incorpo
ration
viru
protein
cell
membran
lindenmann
immun
hamster
highli
purifi
inactiv
vsv
grown
hamster
cell
ansel
induc
transplant
immun
anoth
cell
line
although
similar
immun
vsv
grown
spon
taneous
transform
hamster
cell
line
confer
immun
cell
line
transform
virus
must
stud
i
specif
transplant
reject
antigen
tra
establish
system
also
unclear
whether
tra
incorpor
virion
structur
adsorb
onto
surfac
contamin
host
materi
incorpor
vsv
virion
vide
supra
cell
surfac
antigen
ad
sorb
onto
virion
hecht
summer
studi
viru
purifi
tumor
lysat
tumor
cell
membran
contain
viru
antigen
may
immunogen
thu
eaton
et
al
report
increas
immunogen
gross
viru
lymphoma
syngen
mice
immun
lysat
tumor
cell
infect
ndv
sendai
viru
membran
fraction
effect
concentr
viru
kobayashi
et
al
shown
infect
rat
tumor
friend
viru
increas
immunogen
similar
find
ing
hamster
human
cell
report
use
oncolys
prepar
infect
ndv
axler
girardi
syngen
system
use
cell
transplant
balbc
mice
oncolys
produc
influenza
viru
vsv
yield
similar
result
boon
et
al
boon
et
al
boon
blackman
boon
et
al
found
tumor
immun
induc
viral
oncolys
mice
first
made
toler
viru
cyclophosphamid
treatment
consid
evid
carrierhapten
relationship
viru
tumor
antigen
interpret
difficult
complex
cyclophosphamid
treatment
aisenberg
lagrang
et
al
use
viral
oncolys
human
tumor
improv
im
muniz
effici
patient
tumor
follow
surgeri
radiotherapi
chemotherapi
potenti
import
es
pecial
inactiv
viru
diminish
tumor
im
munogen
infect
cancer
patient
variou
virus
sometim
thought
benefici
effect
webb
howev
critic
evalu
approach
requir
cooper
effect
viru
infect
may
also
prove
use
prepar
antisera
cellular
isoantigen
allogen
system
lindenmann
klein
potent
antilymphocyt
sera
xenogen
system
bandlow
et
al
bandlow
et
al
cooper
phenomena
may
also
help
explain
broaden
reactiv
late
viral
antisera
sinc
immun
respons
minor
viral
determin
may
stimul
respons
stronger
one
certain
type
autoimmun
may
involv
cooper
effect
selfantigen
coupl
strongli
immunogen
viral
antigen
infect
shown
immun
chicken
egggrown
influenza
viru
result
antibodi
product
autolog
mucopolysaccharid
antigen
vide
supra
present
embryolog
endoderm
cell
line
allanto
cav
iti
liver
bile
adult
harbo
hauken
harbo
et
al
patholog
lesion
report
viru
particl
found
nzb
mice
manifest
mani
autoimmun
phenomena
mellor
et
al
dog
lupu
syndrom
lewi
possibl
patient
system
lupu
erythematosu
review
andr
et
al
role
virus
autoimmun
phenomena
yet
clearli
defin
sever
virus
known
influenc
activ
immun
system
see
review
notkin
et
al
mani
viru
infect
result
nonspecif
immunoglobulin
elev
ldv
vee
rauscher
leukemia
aleutian
mink
diseas
equin
infecti
ane
mia
depress
leukomogen
virus
infect
aleutian
mink
diseas
viru
result
elev
immunoglobulin
diminish
humor
respons
unrel
antigen
porter
et
al
kenyon
lodmel
et
al
mice
fect
murin
leukemogen
virus
diminish
circu
late
antibodi
sheep
erythrocyt
bovin
serum
albumin
jern
plaqu
techniqu
use
demonstr
cellular
level
diminish
respons
sheep
erythrocyt
mice
infect
mous
cmv
rowsonparr
viru
bendinelli
nardini
friend
viru
salaman
wedderburn
chan
et
al
rauscher
leukemogen
viru
siegel
et
al
bennett
steev
moloney
leukemogen
viru
salaman
wedderburn
cellmedi
immun
may
also
affect
shown
pro
long
skingraft
reject
mice
follow
infect
ldv
dent
et
al
howard
et
al
marek
diseas
viru
pur
chase
et
al
ndv
woodruff
woodruff
von
pirquet
note
measl
infect
result
decreas
dermal
hypersensit
tuberculin
phenomenon
observ
natur
measl
infect
nablant
beck
shortli
vaccin
attenu
viru
mellman
wetton
brodi
mcalist
starr
berkovich
transient
diminish
skin
test
respons
tigen
candida
vaccinia
viru
dinitrochlorobenzen
poison
ivi
also
observ
follow
attenu
measl
viru
vaccin
blumhardt
et
al
fireman
et
al
lymphocyt
subject
recent
vaccin
attenu
viru
show
transient
diminish
blastogenesi
dna
synthesi
vitro
expos
measl
antigen
tuberculin
candida
antigen
appropri
concentr
pha
smithwick
berkovich
fireman
et
al
finkel
dent
yamanouchi
et
al
report
mark
suppress
dermal
hypersensit
ppd
sensit
rabbit
week
follow
infect
rinderpest
viru
transient
suppress
tuberculin
sensit
also
port
viral
infect
suppress
observ
acut
phase
paralyt
poliomyel
carneval
iovino
immun
tubercul
children
sabin
vaccin
berkovich
starr
latter
author
port
onethird
tubercul
children
studi
becam
tuber
culin
neg
week
sabin
immun
state
persist
long
month
long
delay
vaccina
tion
suppress
unexplain
author
starr
berkovich
report
tubercul
children
varicella
infect
becam
tuberculin
neg
near
end
incub
period
exanthem
reactiv
turn
normal
day
nonspecif
function
clearanc
reticuloendotheli
system
re
may
depress
ldv
ectromelia
lcm
dengu
sandfli
fever
elev
vee
murin
leukemia
virus
viru
infect
infect
ldv
present
special
exampl
impair
clearanc
follow
infect
phagocyt
activ
re
reflect
carbon
particl
clearanc
transient
impair
mahi
perman
impair
clearanc
certain
enzym
ldh
isocitr
dehydrogenas
malat
dehydrogenas
aspart
transaminas
other
alkalin
phosphatas
alanin
transaminas
littl
consider
given
clearanc
endogen
enzym
enzym
use
intracellularli
becom
extracellular
due
cell
leakag
cell
death
known
extracellular
function
long
held
re
play
role
clear
protein
gener
alli
hyman
paldino
base
studi
show
decreas
clearanc
endogen
enzym
re
blockad
wakim
fleisher
suggest
similar
role
re
clear
endogen
protein
infect
ldv
replic
almost
exclus
macrophag
vitro
appear
specif
elimin
impair
function
subpopul
macrophag
cell
re
respons
clearanc
certain
endogen
enzym
specif
clearanc
cell
certain
enzym
presum
nonimmunolog
basi
sinc
evid
suggest
extracellular
enzym
structur
antigen
alter
therefor
anim
toler
one
postul
specif
membran
receptor
en
zyme
clear
exist
particular
popul
cell
infect
ldv
select
tropism
ldv
may
prove
use
tool
defin
explor
function
subpopul
macro
phage
especi
regard
clearanc
function
mani
way
viru
infect
influenc
im
mune
system
lytic
infect
may
affect
thymu
row
capp
describ
viru
recent
character
herpesviru
parker
et
al
caus
transient
massiv
destruct
thymu
cortex
medulla
newborn
mice
studi
cross
h
mors
person
commun
demonstr
viru
call
thymic
agent
replic
thymocyt
newborn
mice
later
found
salivari
gland
sever
week
infect
lymphocyt
thymu
lymph
node
spleen
minim
reactiv
graftversushost
reaction
lymph
node
cell
show
normal
reactiv
week
postinfect
mitogen
respons
lymphocyt
mitogen
lipopolysaccharid
also
depress
week
g
h
cohen
person
com
munic
human
herpesviru
varicellazost
also
grow
thymu
cheathem
et
al
observ
evid
viru
growth
thymus
children
die
fatal
varicella
infect
mani
intranuclear
inclus
bodi
seen
thymu
reticular
cell
hassal
corpuscl
necrot
measl
infect
human
result
thymu
chang
white
boyd
studi
autopsi
materi
eight
children
less
year
age
die
shortli
measl
infec
tion
begin
day
onset
ill
sever
aggreg
syncyti
format
thymocyt
thymu
cortex
subsequ
total
loss
cortex
case
recoveri
cortex
discern
month
infect
exami
nation
lymphoid
tissu
includ
spleen
mesenter
lymph
node
reveal
similar
chang
tissu
cultur
promin
cytopath
effect
measl
infect
syncyti
forma
tion
ender
peebl
white
boyd
felt
syncyti
cell
format
thymu
differ
warthinfinkeldey
giant
cell
warthin
found
peripher
lymphoid
tissu
prodrom
stage
measl
difficult
relat
thymu
observ
previous
note
suppress
delay
hypersensit
reaction
measl
infect
sinc
mice
least
effect
thymectomi
cellmedi
immun
seen
week
like
immunosuppress
occur
mccullough
et
al
rinderpest
viru
infect
rabbit
yamanouchi
et
al
infect
mice
ldv
caus
transient
deplet
thymusdepend
area
lymph
node
spleen
fig
profbtt
et
al
although
ldv
grow
macro
phage
cultur
replic
lymphocyt
cultur
demonstr
electron
microscopi
within
lympho
cyte
infect
spleen
snodgrass
postul
toxic
effect
lymphocyt
mediat
viral
growth
den
dritic
macrophag
near
lymphocyt
disrupt
tropic
influenc
releas
toxic
materi
alter
lympho
cyte
migrat
could
also
result
peripher
lymphoid
necrosi
common
featur
infect
mous
hepat
viru
hirano
ruebner
biggart
ruebner
well
medipest
virus
alreadi
mention
bursal
infecti
agent
avian
viru
caus
lymphoid
necrosi
young
chicken
result
syndrom
term
gumboro
diseas
replic
thymu
lymph
node
spleen
bursa
fabriciu
chevil
sever
inflammatori
reaction
occur
bursa
lym
phoid
organ
repopul
lymphocyt
infect
infect
viral
antigen
viru
particl
de
tect
macrophag
bursa
affect
lympho
cyte
damag
lymphocyt
may
therefor
indirect
po
sibli
autoimmun
natur
mani
virus
known
replic
lymphocyt
mim
gresser
lang
edelman
wheelock
wheelock
toy
infect
may
result
chromosom
abnormali
tie
nichol
cell
death
persist
infect
may
result
subtl
disturb
cell
function
hypothes
infect
lymphocyt
may
alter
protein
synthesi
respons
hormon
interact
lymphoid
cell
mac
rophag
antigen
migrat
characterist
migrat
lymphocyt
vivo
partli
determin
cell
membran
charac
terist
sialic
acid
content
woodruff
gesner
berney
gesner
surfac
infect
cell
often
al
tere
vide
supra
appear
cell
membran
viral
neuraminidas
infect
result
releas
cell
membran
sialic
acid
klenk
et
al
woodruff
woodruff
report
inocul
ndv
rat
caus
transient
divers
home
thorac
duct
lymphocyt
lymph
node
spleen
liver
result
deplet
lymphocyt
thymusdepend
area
node
spleen
appear
due
viral
neuraminidas
act
lymphocyt
surfac
import
phenomenon
natur
infect
clear
theoret
latent
infect
lymphocyt
might
convert
product
lytic
infect
lymphocyt
stimul
divid
viru
activ
occur
graftversushost
reaction
mix
lymphocyt
reaction
hirsch
et
al
duce
virus
endogen
leukemogen
virus
found
pri
marili
blastogen
lymphocyt
et
al
pre
sumabl
viral
genom
present
phenotyp
normal
cell
postul
oncogen
theori
todaro
huebner
activ
process
trigger
allogen
stimu
lu
import
immunologi
activ
virus
human
diseas
suggest
high
incid
malign
re
found
renal
allograft
patient
penn
starzl
rele
vant
hirsch
et
al
report
mice
receiv
al
treatment
well
allograft
increas
incid
ac
tivat
virus
spleen
compar
receiv
allo
graft
without
al
treatment
anim
receiv
al
alon
produc
viru
thu
hostversusgraft
reaction
activ
oncogen
virus
especi
host
receiv
al
therapi
human
lymphocyt
stimul
al
replic
vsv
edelman
wheelock
hsv
kleinman
et
al
higher
titer
untreat
cell
activ
nononcogen
virus
lymphocyt
allogen
stimul
suggest
cytomegaloviru
posttran
fusion
syndrom
isol
cmv
donor
recipi
prior
blood
transfus
rare
mirkov
et
al
lymphocytelymphocyt
interact
may
requir
similar
situat
may
exist
eb
viru
activ
transfus
whether
sever
chronic
infect
may
also
activ
virus
known
virus
vsv
wheelock
yellow
fever
wheelock
edelman
mump
duenguyen
henl
hsv
nahmia
et
al
grow
l
l
e
f
lymphocyt
unless
stimul
pha
antilymphocyt
sera
edelman
wheelock
vsv
appear
grow
predominantli
blastogen
lymphocyt
perhap
preferenti
cytotox
potenti
kano
et
al
concanavalin
pokewe
mitogen
stimul
spleen
lym
phocyt
result
increas
viru
plaqueform
cell
respect
lipopolysaccharid
stimul
sult
twofold
increas
background
prior
treatment
cell
sera
complement
use
athym
nude
mous
spleen
cell
result
viru
plaqueform
cell
mix
cultur
cba
lymphocyt
produc
mani
cytotox
lymphocyt
larg
number
viru
plaqueform
cell
observ
cultur
balbc
lymphocyt
result
even
blastogenesi
less
cytotox
viru
plaqueform
cell
observ
infect
virus
requir
lymphocyt
prolifer
replic
occur
fortuit
activ
latent
state
time
antigen
stimul
might
elimin
rapidli
divid
clone
immunocompet
cell
specif
stimul
antigen
conceiv
viru
lyric
infect
lymphoid
cell
time
respond
antigen
stimulu
provid
viru
might
elimin
clone
immun
cell
specif
viru
antigen
thu
specif
state
toler
similar
produc
cyclophosphamid
treatment
anim
tigen
exposur
viru
infect
nathanson
cole
might
aris
sever
approach
taken
establish
popul
lymphocyt
primarili
affect
viru
infect
abil
infect
cell
particip
graftversushost
reaction
pur
chase
et
al
howard
et
al
bennett
steev
reject
skin
graft
howard
et
al
stimul
pha
vitro
allogen
exposur
hagri
et
al
use
determin
immunocompet
infect
lymphocyt
transferreconstitut
experi
infect
bone
marrow
cell
use
ascertain
b
lymphocyt
compet
bennett
shearer
et
al
interpret
experi
difficult
sinc
transfer
infect
cell
often
result
transfer
infecti
viru
well
experi
friend
viru
particularli
complic
contamin
rowsonparr
viru
lymphat
leukemia
viru
ldv
bennett
recent
transferreconstitut
experi
shearer
et
al
demonstr
antibodi
respons
damino
acid
polypeptid
thymusindepend
antigen
significantli
duce
infect
bone
marrow
cell
sjlj
leukemogen
viru
regardless
whether
thymocyt
infect
henc
infect
viru
may
result
decreas
respons
b
lymphocyt
experi
provid
informa
tion
possibl
effect
lymphocyt
pele
haranghera
found
infect
mice
radiat
leukemia
gross
viru
result
depress
respons
spleen
cell
sheep
erythrocyt
normal
respons
thymusindepend
antigen
polyvinylpyrrolidin
pneumococc
polysaccharid
siii
conclud
immunosuppress
effect
viru
lymphocyt
direct
effect
measl
viru
infect
lymphocyt
investig
h
mcfarland
person
commun
mouseadapt
strain
viru
use
infect
mice
measl
antigen
present
spleen
day
inocul
lymphocyt
kill
demonstr
normal
number
lymphocyt
sensit
complement
mice
prime
ovalbumindnp
oadnp
carrierhapten
conjug
chicken
cgg
secondari
carrier
spleen
cell
use
combin
adopt
immun
irradi
recipi
mice
secondari
antihapten
respons
measur
chal
leng
appropri
conjug
effect
measl
viru
fection
ascertain
infect
either
cgg
prime
donor
oadnp
prime
donor
found
infect
cgg
prime
donor
result
diminish
antihapten
respons
infect
oadnp
donor
effect
respons
sindbi
viru
infect
carrier
donor
affect
respons
although
studi
demonstr
effect
measl
viru
infec
tion
helper
cell
popul
lymphocyt
impair
lymphocyt
activ
may
respons
observ
im
pairment
delay
hypersensit
final
viru
infect
abrog
toler
inocul
balbc
mice
subimmunogen
amount
pneumococc
polysaccharid
siii
rel
thymusindepend
antigen
result
unrespons
subsequ
immunogen
amount
antigen
state
last
month
specif
siii
baker
et
al
toler
system
appear
mediat
suppressor
cell
sinc
broken
administr
al
along
siii
also
toler
siii
induc
athym
nude
mice
p
j
baker
w
h
burn
unpublish
observ
found
infect
ldv
abrog
toler
although
lesser
ex
tent
al
administr
due
adjuv
effect
sinc
wellknown
adjuv
like
complet
freund
adjuv
poli
ic
lipopolysaccharid
abrog
toler
system
figur
show
hour
infect
thymusdepend
area
spleen
lymph
node
deplet
lymphocyt
appear
lymphoid
tissu
follow
administr
al
whether
ldv
alter
cell
migrat
directli
indi
rectli
toxic
cell
clear
doubt
viru
selec
tive
impair
function
suppressor
cell
rather
impair
function
cell
system
siii
tigen
predomin
influenc
cell
specif
b
cell
suppress
one
destruct
impair
cell
function
result
diminut
suppress
effect
thu
demon
strate
viru
infect
unbal
normal
regulatori
mechan
immun
system
frequenc
viru
infec
tion
anim
presenc
endogen
virus
cell
persist
latent
infect
exogen
virus
mani
cell
requir
awar
immunologist
influenc
virus
immun
respons
past
two
decad
scienc
immunolog
ad
vanc
rapidli
variou
class
subclass
immunoglobulin
recogn
structur
properti
elucid
interact
b
lymphocyt
macrophag
induct
immun
respons
extens
docu
ment
reaction
receptor
immunoglobulin
b
lymphocyt
mechan
synthesi
immunoglobulin
prog
eni
analyz
product
lymphocyt
activ
anti
gen
mitogen
defin
effect
macro
phage
cell
studi
compon
complement
system
isol
character
altern
path
activ
complement
system
recogn
time
consider
advanc
made
molec
ular
virolog
genet
structur
virus
nucleic
acid
specif
polymeras
involv
replic
mechan
synthesi
protein
glycoprotein
compon
capsid
envelop
studi
detail
genet
anim
virus
genet
control
immun
respons
receiv
increas
attent
temperaturesensit
mutant
virus
use
studi
mode
replic
mechan
malign
transform
human
patient
experiment
anim
inherit
defici
immunoglobulin
complement
compon
format
thymu
defi
cienci
alreadi
provid
valuabl
inform
differen
tial
suscept
infect
part
develop
immunolog
virolog
genet
parallel
independ
futur
ac
cumul
inform
power
analyt
method
develop
disciplin
pool
combin
approach
problem
far
seem
intract
benefit
sort
approach
alreadi
appar
mani
remark
featur
humor
immun
respons
came
light
cours
studi
antibodi
virus
includ
earliest
analys
secretori
antibodi
later
shown
mainli
iga
specif
featur
immunologi
memori
origin
antigen
sin
igm
memori
follow
repeat
exposur
small
dose
antigen
cellular
basi
respons
still
imperfectli
understood
high
sensit
plaqu
neutral
system
viral
antigen
offer
interest
materi
studi
current
studi
analyz
cellular
level
format
b
lymphocyt
memori
respons
b
cell
crossreact
antigen
influenc
lymphocyt
recal
provid
basic
knowledg
concern
b
lymphocyt
interact
studi
begun
thymu
depend
viral
antigen
resembl
protein
thymusdepend
howev
one
sindbi
envelop
glycoprotein
rela
tive
thymusindepend
biochem
analysi
mole
cule
may
provid
insight
concern
interest
properti
scienc
immunolog
began
observ
jenner
later
von
pirquet
bodi
respons
benefici
patholog
ical
viru
infect
devast
effect
patient
thymu
defici
viru
infect
usual
mild
normal
human
first
indic
biolog
import
cellmedi
immun
viru
infect
ectromelia
viru
experiment
anim
provid
model
system
analyz
vivo
role
variou
lymphoid
cell
recent
develop
vitro
assay
variou
lymphocyt
function
make
feasibl
correl
ativ
studi
vivo
activ
differ
lymphocyt
popula
tion
interest
inform
studi
particularli
use
lcm
viru
alreadi
discuss
mechan
immun
mediat
lymphocyt
part
play
protect
viru
infect
still
imper
fectli
understood
still
less
known
biolog
impor
tanc
cytotox
system
antibodi
sensit
virusinfect
target
cell
destruct
nonspecif
effector
k
lymphoid
cell
recent
shown
occur
vitro
herpesvirusinfect
cell
could
play
role
immun
immunopatholog
ragerzisman
bloom
shore
et
al
model
system
viral
infect
use
defin
import
phenomenon
final
although
first
note
von
pirquet
almost
year
ago
effect
viru
infect
immun
respons
recent
receiv
much
attent
alreadi
discuss
presenc
viral
antigen
less
immunogen
antigen
may
enhanc
respons
latter
virus
infect
affect
particular
popul
lym
phoid
cell
eg
thymic
agent
ldv
report
latter
abrog
toler
certain
antigen
tropism
virus
may
prove
use
properti
select
deplet
anim
certain
lymphocyt
popul
caus
role
virus
diseas
autoimmun
phenomena
still
rela
tive
unexplor
